

1 **Far from the gut but still relevant?**

2 **Circulating bacterial signature is linked to metabolic disease and shifts with**  
3 **metabolic alleviation after bariatric surgery**

4 **Short title: Blood bacterial signature and metabolic health**

5 Rima M. Chakaroun<sup>1\*#</sup>, Lucas Massier<sup>1\*</sup>, Anna Heintz-Buschart<sup>3,4</sup>, Nedal Said<sup>1,2</sup>, Joerg  
6 Fallmann<sup>7</sup>, Alyce Crane<sup>1</sup>, Tatjana Schütz<sup>1</sup>, Arne Dietrich<sup>5</sup>, Matthias Blüher<sup>1,6</sup>, Michael  
7 Stumvoll<sup>1</sup>, Niculina Musat<sup>2</sup>, Peter Kovacs<sup>1</sup>

8 **Affiliations:**

9 1: Medical Department III – Endocrinology, Nephrology, Rheumatology, University of Leipzig Medical Center,  
10 04103 Leipzig, Germany

11 2: Department of Isotope Biogeochemistry, Helmholtz Centre for Environmental Research – UFZ Leipzig

12 3: German Centre for Integrative Biodiversity Research (iDiv) Halle-Jena-Leipzig, 04103 Leipzig, Germany

13 4: Helmholtz Centre for Environmental Research GmbH – UFZ, 06120 Halle, Germany

14 5: Leipzig University Hospital, Department of Visceral, Transplantation, Thoracic and Vascular Surgery, Section of  
15 Bariatric Surgery, 04103 Leipzig, Germany

16 6: Helmholtz Institute for Metabolic, Obesity and Vascular Research (HI-MAG) of the Helmholtz Zentrum München  
17 at the University of Leipzig and University Hospital Leipzig

18 7: Department of Computer Science and Interdisciplinary Center for Bioinformatics, University of Leipzig, Leipzig,  
19 Germany

20 \*contributed equally

21 # corresponding author

22

23 **Corresponding author:**

24 **Rima M. Chakaroun**, Mailing address: Liebigstr. 20, 04103 Leipzig, Germany. Phone: +49-341-  
25 9713377. Fax: +49-341-9713389. E-mail: rima.chakaroun@medizin.uni-leipzig.de

26

## 27 Abstract

### 28 Background

29 The microbiome has emerged as an environmental factor contributing to obesity and type 2 diabetes (T2D).  
30 While the majority of studies have focused on associations between the gut microbiome and metabolic  
31 disease, increasing evidence suggests links between circulating bacterial components (i.e. bacterial DNA)  
32 and cardiometabolic disease as well as blunted response to metabolic interventions such as bariatric surgery.  
33 In this aspect, thorough next generation sequencing based and contaminant aware approaches are lacking.  
34 To address these points, we tested whether bacterial DNA could be amplified in the blood of subjects with  
35 obesity and high metabolic risk under strict experimental and analytical control to minimize bacterial  
36 contamination. Moreover we characterized a bacterial signature associated with the individual metabolic  
37 risk and explored its dynamics alongside metabolic improvement after bariatric surgery.

### 38 Methods

39 Subjects undergoing elective bariatric surgery were recruited into sex and BMI matched subgroups with  
40 (n=24) or without T2D (n=24). Bacterial DNA in the blood was quantified and prokaryotic 16S rRNA gene  
41 amplicons were sequenced. A contaminant aware approach was applied to derive a compositional microbial  
42 signature from bacterial sequences in subjects with and without T2D and within subjects at baseline and at  
43 three and twelve months post bariatric surgery. We modelled associations between bacterial load and  
44 composition with host metabolic and anthropometric markers. We further tested whether compositional  
45 shifts were related to weight loss response and T2D remission after bariatric surgery. Lastly, Catalyzed  
46 Reporter Deposition (CARD) - Fluorescence *In Situ* Hybridization (FISH) was employed to visualize  
47 bacteria in blood samples.

48 **Results**

49 Contaminant aware classification of bacterial 16S rRNA sequences allowed the derivation of a blood  
50 bacterial signature, which was associated with metabolic health. Based on bacterial phyla and genera  
51 detected in the blood samples, a metabolic syndrome classification index score was derived and shown to  
52 robustly classify subjects along their actual clinical group. T2D was characterized by decreased bacterial  
53 richness and a loss of genera associated with improved metabolic health. Moreover, circulating bacterial  
54 load was significantly associated with metabolic health and increased after bariatric surgery. Weight loss  
55 and metabolic improvement following bariatric surgery were associated with an early and stable increase  
56 of these genera in parallel with improvements in key cardiometabolic risk parameters. CARD-FISH allowed  
57 the detection of living Bacteria in blood samples in obesity.

58 **Conclusions**

59 We show that the circulating bacterial signature reflects metabolic disease and its improvement after  
60 bariatric surgery. Our work provides contaminant aware evidence for the presence of living bacteria in the  
61 blood and suggests a putative crosstalk between components of the blood and metabolism in metabolic  
62 health regulation.

63 **Key words:** blood bacteria; obesity; metabolic syndrome; type 2 diabetes; bariatric surgery

## 64 **Main Text**

### 65 **Introduction**

66 The major health burden of obesity is largely attributable to its associated diseases such as type 2 diabetes  
67 (T2D), the metabolic syndrome (MetS) and cardiovascular diseases. Along with known risk factors, such as  
68 genetic predisposition, poor diet and lower physical activity, shifts in the gut microbial composition have  
69 been shown to contribute to metabolic inflammation at the advent of obesity and T2D [1–5]. Beyond  
70 composition, low gut bacterial diversity has been associated with increased obesity, insulin resistance,  
71 dyslipidemia and increased inflammation [6, 7]. More recently, low gut bacterial load has been identified  
72 as a key driver related to chronic inflammatory states such as Crohn’s disease [8]. Converging evidence  
73 further points to an important role of the gut microbiome as a therapeutic target and prognostic marker:  
74 Weight loss interventions, such as diet and bariatric surgery, profoundly affect the gut microbiota  
75 composition, leading to an increased bacterial gene count and bacterial richness. This, in turn, is associated  
76 with a decrease in inflammatory markers and an increase in insulin sensitivity up to complete remission of  
77 T2D [9–11]. Accordingly, weight loss interventions are less effective in improving insulin resistance and  
78 inflammatory state in patients with low bacterial gene diversity [7].

79 Although most evidence has been submitted for the gut microbiome, host tissues – including blood [12],  
80 liver and adipose tissue [13, 14]– have been shown to accommodate microbial consortia finally accessible  
81 through culture independent techniques. Few studies further linked increased bacterial DNA load in the  
82 circulation with the incidence of T2D [15, 16] and cardiovascular disease [17]. Moreover, bacterial  
83 signature in the blood has been linked to the circulatory compartment it derives from (i.e. systemic vs. portal  
84 circulation) [18], systemic inflammation [18], T2D presence [13, 14, 19] and metabolic disease severity  
85 [20]. Similarly, there is mounting evidence for diagnostic application of blood based bacterial DNA  
86 highlighted in a recent work employing contaminant-aware approaches to show that it can discriminate

87 between multiple types of cancer and is highly dependent on disease severity [21]. On the other hand, only  
88 one study contemplated the interplay between metabolic interventions and circulating bacterial markers:  
89 Subjects with an established bacterial DNA translocation based on qPCR detection did not experience a  
90 remission of T2D or significant improvement in insulin sensitivity despite significant weight loss after  
91 bariatric surgery [22]. These results advocate a closer look at blood-borne bacterial DNA and bacterial  
92 signatures and their role in health and disease.

93 It is worth noting that studies on bacterial load and composition in low bacterial biomass environments such  
94 as the blood are subject to technical biases including highly underestimated environmental contamination  
95 [23]. To our knowledge, only few studies have actively controlled for contamination so far [13, 14, 21],  
96 and only two included a bioinformatic contaminant aware approach [13, 14]. We therefore applied a  
97 contamination aware approach to test the hypothesis that the presence, composition and load of bacterial  
98 DNA in the blood reflects obesity, metabolic risk factors and inflammatory burden as well as weight loss  
99 associated changes in anthropometric and metabolic parameters after bariatric surgery.

## 100 **Research design and methods**

### 101 **Characterization of study participants and sample collection**

102 64 subjects were recruited at the University of Leipzig Medical Center, Germany, after matching for BMI  
103 and sex differing on T2D status with 32 subjects having no T2D and 32 with T2D according to ADA-  
104 criteria (19). However, 16 subjects had to be excluded from longitudinal comparisons due to missing  
105 follow-ups in at least one time point (n=15) or missing follow-up phenotypes (n=1). If not indicated  
106 otherwise, 48 subjects (24 with T2D, 24 without) were included in all analyses (**table 1-** baseline cohort  
107 characteristics of subjects with complete follow-up (n=48), **supplementary table 1-** baseline cohort  
108 characteristics with initial matching (n=64)). Individuals fulfilled the following inclusion criteria: 1)  
109 Eligibility to bariatric surgery according to international clinical guidelines (BMI  $\geq 40$  kg/m<sup>2</sup>, or  $\geq 35$

110 kg/m<sup>2</sup> with at least one obesity associated metabolic disease) and internal clinical multidisciplinary panel,  
111 2) no chronic or acute inflammatory disease as determined by blood cell counts and CRP or clinical signs  
112 of infection, 3) no evidence of coronary or peripheral artery disease, 4) no known thyroid dysfunction, 5)  
113 no antibiotics intake three months prior to the study visit, 6) no pregnancy or nursing, and 7) no NSAIDs  
114 intake within 78 h prior to the study visit.

115 Subjects were extensively phenotyped before bariatric surgery and at month three and twelve post bariatric  
116 surgery, including clinical and anthropometric assessment in conjunction with evaluation of patient medical  
117 history and physical examinations. Among other parameters, blood pressure, waist and hip circumference  
118 measurements as well as bioimpedance measurement for body composition analysis, including automatic  
119 calculation of visceral fat rating, (BC-418 MA, Tanita, Tokyo, Japan) were assessed. Obesity associated  
120 diseases such as T2D [24], hypertension [25] and hyperlipidemia [26] were defined according to medical  
121 association definition of the specific disease. Metabolic syndrome (MetS) was defined according to  
122 international conventions [27]. Excess BMI loss (EBL) was calculated as follows:  $EBL = (BMI_{baseline} -$   
123  $BMI_{12\ months}) / (BMI_{baseline} - 25) * 100$  [28] and poor response was defined as an EBL <50%, whereas a  
124 good response was defined as an EBL >60% (adapted from [28]) (**supplementary table 2**– phenotypes  
125 of good vs poor responders).

## 126 **Replication Cohort**

127 To validate results from bacterial quantification and associations thereof with host parameters, data from a  
128 subgroup consisting of 62 subjects belonging to a previously described cohort from the same center were  
129 analysed (**supplementary table 3 – phenotypes replication cohort**). Phenotyping procedures and cohort  
130 description of the whole cohort are available elsewhere [14].

131

## 132 **Samples preparation**

133 Blood samples were collected after an overnight fast at each time point, and EDTA-blood samples were  
134 collected for DNA isolation and stored at -20°C. Fasting plasma glucose was measured using the

135 hexokinase method, HDL- and LDL-cholesterol were measured using enzymatic assays and insulin was  
136 measured using chemiluminescence assay according to standard laboratory procedures. C-reactive protein  
137 (CRP) was measured using an Image Automatic Immunoassay System (Beckman Coulter). All  
138 measurements were performed according to routine laboratory procedures. Homeostasis Model Assessment  
139 of Insulin Resistance (HOMA-IR) was calculated as previously described [29]. Lipopolysaccharide binding  
140 protein (LBP) was measured using the HK315 HUMAN LBP ELISA Kit (Hycult Biotech, Uden,  
141 Netherlands) according to the manufacturer's recommendations. Samples and follow up availability dictated  
142 the numbers of used samples for analyses at each step as illustrated in **supplementary figure 1**.

## 143 **Bacterial DNA extraction, quantification and amplification for sequencing**

### 144 **Bacterial DNA extraction**

145 To minimize contamination, all steps were performed under a sterile class II laminar flow hood using  
146 aseptic measures including the use of one-way lab coats, elbow-length gloves as well as facemasks. All  
147 non-organic liquids and required materials were subjected to at least 120 minutes of UV-radiation.  
148 Furthermore, negative controls consisting of UV-treated PBS (filled in EDTA vials using venipuncture  
149 ware from the same batch to simulate venous puncture) were included and carried through all experimental  
150 procedures, including sequencing.

151 DNA was extracted from 200 µl whole EDTA-blood using the QIAMP Blood MiniKit (Qiagen, Germany)  
152 following the manufacturer's recommendations with an additional lysozyme step at 37 °C overnight (0.25  
153 mg/ml, L7615, Sigma-Aldrich, MO, USA). DNA yield, integrity and quality were assessed using Quant-iT  
154 PicoGreen dsDNA kit (Invitrogen, CA, USA) and Nanodrop 2000 spectrometer (Thermo Fisher Scientific,  
155 MA, USA).

## 156 **Quantification of bacterial 16S rRNA gene**

157 Bacterial DNA was quantified by qPCR amplification of the bacterial 16s rRNA gene using previously  
158 published primers (F\_Bact 1369: 5'-CGGTGAATACGTTCCCGG-3' and R\_Prok 1492:5'-  
159 TACGGCTACCTTGTTACGACTT-3') [17, 30, 31]. All qPCR reactions were performed in duplicate each  
160 using 50 ng of whole extracted DNA, prepared in a PCR clean room and run on a LightCycler 480  
161 (Hoffmann-La Roche, Basel, Switzerland) with the following conditions: 50 °C for 2 min, 95 °C for 10  
162 min and 40 cycles of denaturation at 95 °C for 15 s, annealing at 60 °C for 30 sand extension at 72 °C for  
163 30 s. The amount of amplified bacterial DNA was calculated using mean Cp values for each duplicate  
164 against a standard curve from E. coli JM 109 DNA dilutions (Promega, MA, USA) , which included seven  
165 duplicates ranging from 1.25 fg to 0.2 ng total bacterial DNA. Quantification of the analyzed samples was  
166 performed in three runs with  $R^2 \geq 0.995$  and a mean PCR efficiency of  $2.06 \pm 0.03$ . Analysis was conducted  
167 according to the Livak method [32]. Results were in concordance with a commercially available kit  
168 (Zymoresearch, CA, USA) (n=13, r=0.74, p=0.004) and proved more sensitive ( $\Delta Ct=3.9$ ). Obtained  
169 concentrations were normalized to the total concentration of extracted DNA as well as the used blood  
170 volume and is given as pg bacterial DNA per  $\mu\text{g}$  of isolated DNA. This is due to the variation of amounts  
171 of total extracted DNA from the same 200  $\mu\text{l}$  blood volume for each sample, which ranged from 12.7 - 98.2  
172 ng/ $\mu\text{l}$ . Blood bacterial quantity in the replication cohort (**supplementary table 3**) was independently  
173 measured according to the same protocol. To overcome inter-assay variability, blood bacterial load was  
174 standardized (z-score transformation) within the cohorts and analyses were conducted on standardized  
175 bacterial quantities for each cohort separately as well as both of them combined.

## 176 **16S rRNA gene sequencing analysis**

177 After extensive testing of combinations of primers and polymerases for amplification of prokaryotic /  
178 bacterial 16S rRNA variable regions [14], V4-V5 primers adapted from the Ribosomal Database Project  
179 (RDP) (V4-F: 5'-ACTGGGCGTAAAGCG-3'; V5-R: 5'-CCGTCAATTCCTTTGAGTTT-3') were used

180 [33]. PCR reactions were prepared in triplicate in a sterile laminar flow hood and performed using 50 ng  
181 total DNA in a total reaction volume of 25  $\mu$ l containing 1.25  $\mu$ l of each primer (10 $\mu$ M), 12.5  $\mu$ l 2x Q5  
182 Reaction Buffer (including Q5<sup>®</sup> High-Fidelity DNA Polymerase, New England BioLabs, MA, USA) and  
183 6.25  $\mu$ l UV-ed PCR-grade water. The reaction was carried out on a LightCycler 480 (Hoffmann-La Roche,  
184 Basel, Switzerland) under the following conditions: 98 °C for 2 min and 40 cycles of denaturation at 98 °C  
185 for 30 s, annealing at 58 °C for 30 s and extension at 72 °C for 30 sec. Each PCR reaction included at least  
186 3 negative controls in addition to the extraction controls (blank controls) and the absence of detectable PCR  
187 products in these negative controls was confirmed by gel electrophoresis. Regardless of this, negative  
188 controls for each run were pooled and carried through sequencing to be used for contaminant identification.  
189 Replicate amplicons were pooled and purified using Agencourt Ampure magnetic purification beads  
190 (Beckman Coulter Indianapolis, IN, USA) according to the manufacturer's protocol to remove short  
191 amplification products and primer dimers. DNA amounts were quantified using Quant-iT PicoGreen  
192 dsDNA kit (Invitrogen, CA, USA). Library preparation and paired-end sequencing were performed  
193 commercially (BGI Genomic, Shenzhen, China) on Illumina Hiseq2500 technology and using custom  
194 fusion-primers in a one-step PCR approach.

## 195 **Bioinformatics and statistical analyses**

### 196 **Statistical analyses**

197 Statistical analyses were performed in R v3.5.0 (R Development Core Team, 2008). Prior to statistical  
198 testing, distribution as well as single test assumptions were checked and statistical tests were chosen  
199 accordingly. For cross-sectional comparisons between two groups, Wilcoxon signed-rank-test was used  
200 for non-normally distributed variables according to Shapiro-Wilk testing, whereas unpaired Student's t-test  
201 was used to compare normally distributed variables. Median and first as well as third quartile limits are  
202 depicted for non-normally distributed variables, whereas for normally distributed continuous variables, data  
203 are given in mean  $\pm$  standard deviation (SD). Friedman-test was used to compare dependent groups at

204 different time points. Categorical parameters were analyzed using the Chi-square test. Bivariate correlation  
205 analyses were performed using spearman's rank correlation test. Figures were generated using ggplot2 [34]  
206 v3.1.0, ggpubr v0.2 [35], and corrplot v.0.84 [36] as well as phyloseq v1.26.1 [37] and relabeled in Adobe  
207 Illustrator (Adobe Inc., CA, USA). A p-value threshold of 0.05 was used to depict statistical significance.  
208 Analyses were adjusted for multiple hypotheses *ad modum* Benjamini-Hochberg, in which case a False-  
209 discovery-rate (FDR) of  $P_{adj} < 0.05$  was considered significant.

### 210 **Processing of 16S rRNA reads and amplicon sequence variants (ASV) clustering**

211 A total of 12,857,649 Illumina Hiseq quality filtered paired end reads were obtained from BGI, with  
212 samples having a median read count of 63,055 [9661 – 64,630]. Preprocessing and quality filtering  
213 consisted of removing of reads with a certain proportion of low quality (20) bases (20% of read original  
214 length), contaminated by adapter (5 bases overlapped by reads and adapter with maximal 3 bases mismatch  
215 allowed), with ambiguous bases and with low complexity (reads with 10 consecutive same base).  
216 Subsequently, quality was checked using Multiqc [38] and data was imported to QIIME2 [39] V2019.1 for  
217 analysis (**supplementary file 1 for Qiime2 commands – DOI reserved and citation to follow**  
218 **acceptance**). Denoising, dereplication, merging and chimera-filtering as well as ASV inference were done  
219 in one step using the DADA2 [40] plugin in QIIME 2 resulting in  $40269 \pm 6033$  non-chimeric reads with  
220 an average read length of 329 bp. Reads were truncated at a length of 242 bp. For phylogenetic analyses,  
221 primer-truncated and quality trimmed reads were used to create an alignment using mafft [41]. The  
222 alignment was masked to remove uninformative highly variable regions and a rooted tree was generated  
223 using the align-to-tree-mafft-fasttree plugin. For taxonomic classification a scikit-learn [42] naive Bayes  
224 classifier was created against the taxonomic classification from ARB-SILVA [43] 132 release (99% OTU  
225 data set), which was trained for the used primers. Only reads mapped to bacterial taxonomy were retained.  
226 This resulted in a total of 2860 bacterial ASVs with a total frequency of 7,784,509. Derived taxonomy, tree  
227 and feature table were imported into phyloseq [37] v1.26.1 and all subsequent analyses were performed in  
228 R v 3.5.0 0 (R Development Core Team, 2008).

## 229 **Bacterial contaminants identification in blood samples**

230 A bioinformatic decontamination step using the Decontam [44] package v1.2.1, which is intended for the  
231 identification of contaminants in low bacterial biomass samples, was added. To identify contaminant ASVs,  
232 the “prevalence” method was applied. A binomial distribution with low scores for low prevalence ASVs  
233 was found around 0.1 and high prevalence ASVs with higher confidence increasing around 0.175, which  
234 led us to select a data driven contaminant score of 0.175 instead of the default classification score 0.1  
235 (**supplementary figure 2**). Using these parameters, 114 features were classified as potential contaminants,  
236 and removed, leading to a total of 2746 ASVs (**supplementary file 2**: contaminating ASVs at Decontam  
237 Score 0.175, **supplementary file 3**: taxonomy in samples and negative controls, **supplementary file 4**:  
238 taxonomy in samples after removing contaminant sequences at a contaminant score of 0.175). The pruned  
239 phyloseq object was then used for subsequent analyses. We moreover added a more stringent  
240 decontamination step using a contaminant score of 0.5 leading to flagging of each of the 172 ASVs  
241 appearing in the negative samples as contaminants. While ASVs derived from both decontamination scores  
242 led to similar results in associations of taxonomy with host variables (data not shown), the data driven  
243 decontamination at a lower score was more likely to influence differential abundance analyses. This led us  
244 to use a more stringently decontaminated taxonomy while performing differential abundance testing to  
245 avoid spurious observations. The stringently decontaminated taxonomy included a total of 2688 ASVs.  
246 (**supplementary file 5**: contaminating ASVs at Decontam Score 0.5, **supplementary file 6** : taxonomy in  
247 samples after removing contaminant sequences at a contaminant score of 0.5).

## 248 **Analyses of bacterial composition and its association with host phenotypes**

249 Alpha diversity measures (Shannon diversity, observed richness) were calculated and RDA on Bray-Curtis-  
250 dissimilarity distances was conducted to identify host covariates contributing to bacterial community  
251 composition in the blood in vegan [45] v2.5-4 . Samples with missing observations (NAs) in the covariates  
252 were eliminated from the dataset prior to analyses. Variables used in the RDA model included: T2D Status,  
253 Sex, Metformin use, PPI use, timepoint, MetS status, diabetes alleviation after surgery, EBL, surgical

254 procedure, BMI, systolic blood pressure, eGFR, CRP, HbA1c, HDL-cholesterol, LDL-cholesterol,  
255 triglycerides, total fat mass in %, visceral fat ratio, number of antidiabetics, number of antihyperlipidemic  
256 drugs, number of antihypertensive drugs, white blood cells count, age, bacterial load and waist-to-hip-ratio.  
257 We further used automatic stepwise modelling and model selection using the ordistep approach both ways  
258 with 999 permutations to identify the most significant covariates contributing to community composition.  
259 Microbiome [46] v1.4.2.was used to perform correlation analyses between relative taxa abundances and  
260 host variables of interest applying Spearman's rank correlation.

261 A random forest classification (randomForest [47] v4.6-14) approach on both phylum and genus level  
262 abundances was used to develop classification indices for MetS for subjects at baseline. For phylum and  
263 genus level NGS derived read counts from MetS and non-MetS subjects where normalized by the total read  
264 count of the corresponding phylum or genus and used as features for training of a random forest classifier.  
265 The classification index predicted by the machine ranges between 0 and 1 and corresponds to the out-of-  
266 bag predicted probability of being classified as belonging to the class of interest (i.e. having MetS) with  
267 higher scores indicating higher probability for having MetS. Performance of classification indices were  
268 quantified using receiver operating characteristic curve and AUC using pROC [48] v1.14.0. Cross  
269 validation was performed using the rfUtilities package [49, 50] v2.1-5. Specifics of random forest  
270 classification are as follows: Number of trees 500; Number of variables tried at each split 11; OOB estimate  
271 of error rate at genus level 21.3%, at phylum level 29.8%; Classification accuracy for model at genus level:  
272 users accuracy 100, producers accuracy: 79.1, Model kappa=0.147, Model OOB Error=0.204, Model Error  
273 variance=  $4.7 \times 10^{-5}$ ; Classification accuracy for model at phylum level : users accuracy 91.2 , producers  
274 accuracy: 79.5 Model kappa=0.1357, Model OOB error 0.25, Model error variance =  $7.7 \times 10^{-4}$ ).

275 Differential abundance analyses for preassigned dichotomous groups were performed using DESeq2 [51]  
276 v1.22.2. Size factors for count data were calculated using the poscounts estimator. Dispersions estimates  
277 were performed using the DESeq command, a local regression model was used to fit and test the data and  
278 the negative binomial Wald Test was used to test differential abundance ( $\log_2$  fold change) and

279 significance. Results are reported for differentially abundant taxa with a significance  $P_{adj} < 0.01$  after  
280 multiple hypotheses correction *ad modum* Benjamini-Hochberg. Specifically, for the comparison between  
281 T2D remission and no remission following bariatric surgery, only subjects with T2D at baseline were  
282 retained in the analyses (**supplementary figure 3**).

## 283 **Catalyzed Reporter Deposition (CARD) - Fluorescence In Situ Hybridization** 284 **(FISH)**

285 **Blood sample collection and cell separation.** To visualize and quantify bacteria in the blood, samples  
286 from one patient post bariatric surgery ( male, 38 years, currently 60 months post bariatric surgery, current  
287 BMI 30 kg/m<sup>2</sup>, no T2D, no MetS, initial BMI 61.9 kg/m<sup>2</sup> , EBL 54.5%) and a healthy control (male, 50  
288 years, BMI , no known diseases, no medication).were collected before and 30 min after mixed meal intake  
289 on EDTA 1.6 mg/mL to avoid coagulation and kept overnight at 4°C in the fridge. Density gradient  
290 centrifugation was performed in an initial step to separate microbial cells from blood cells. Thus, 5 mL of  
291 80% Nycodenz solution were added at the bottom of a tube containing 5 mL of blood , followed by  
292 centrifugation at 13000 rpm, 4°C for 2 h. After density gradient centrifugation, individual layers consisting  
293 of supernatant and a Nycodenz layer could be separated. Each layer was individually collected and  
294 subjected to serial filtration through two consecutive 3µm and one 0.22µm pore size polycarbonate filters  
295 (GTTP type, 0.2µm pore size PC membrane, 25mm diameter, Merck Millipore, Germany). After filtration,  
296 all filters were washed in 1× UV-ed PBS buffer and were immersed in 4% paraformaldehyde solution (PFA)  
297 in 1×UV-ed PBS buffer for 2h at room temperature. Following chemical fixation, filters were washed in  
298 1× UV-ed PBS buffer, dehydrated in 80% ethanol, air dried and stored at 4°C for CARD-FISH procedure.  
299 **CARD-FISH** was performed following the standard protocol [52] with slight modifications.  
300 Permeabilization in Lysozyme solution (Sigma-Aldrich, MS, USA) (10 µg mL<sup>-1</sup>) in 0.1M Tris-HCL  
301 (pH=7.8) and 0.05M EDTA (pH=8) buffer was done for 30 min at 37°C followed by 0.01M HCL for 10  
302 min at room temperature (RT) with washing steps of 1 min at RT in ultrapure water in between treatments.

303 Hybridization of filter pieces belonging to both 3 $\mu$ m and 0.2 $\mu$ m filters took place for 3 h at 46°C in a pre-  
304 warmed hybridization buffer containing 0.9M NaCl, 20mM Tris-HCl (pH=7.5), 10% (w/v) dextran  
305 sulfate, 0.02% (w/v) SDS, 35% (v/v) formamide (Fluka, Waltham, USA) and 1% (w/v) blocking reagent  
306 (Boehringer, Mannheim, Germany). The HRP-labelled probe applied is specific for Bacteria (EUB 338 ,  
307 Amann et al., 1990) and was used at a concentration of 0.166 ng mL<sup>-1</sup> (HRP-probe stock solution of 50 ng  
308 mL<sup>-1</sup> diluted 1:300 v/v in hybridization buffer). Following hybridization, filter pieces were incubated in 50  
309 mL of pre-warmed washing buffer containing 70mM NaCl, 5mM EDTA (pH=8.0), 20mM Tris-HCl  
310 (pH=7.5), and 0.01% SDS for 15 min at 48°C. After washing, filters were incubated for 15 min at RT in 1 $\times$   
311 PBS (pH=7.6) to equilibrate the HRP-labeled probe. Subsequently, tyramide deposition was performed by  
312 incubating the filters for 20 min at 46°C in the dark in amplification buffer containing 1 $\times$  PBS, 2M NaCl,  
313 0.1% (w/v) blocking reagent, 10% (w/v) dextran sulfate, 0.0015% (v/v) H<sub>2</sub>O<sub>2</sub>, and 1  $\mu$ g mL<sup>-1</sup> Alexa 594-  
314 labeled tyramides (ThermoFisherScientific, MA,USA). Afterwards, the hybridized filters were rinsed in 1 $\times$   
315 PBS for 10 min at RT followed by staining with 4',6-diamidino-2-phenylindole (DAPI) 1 $\mu$ g mL<sup>-1</sup> for 10  
316 min at RT, washing in ultrapure water, air dried and embedded in mounting medium (a mixture of low  
317 fluorescence glycerol mountant (Citifluor AF1, London) and mounting fluid Vecta Shield (Vecta  
318 Laboratories, CA, USA) in a 4:1 v/v ratio and stored at -20°C prior to imaging.

319 **Microscopic Investigation.** Approximately 20-30 randomly selected fields of view (each of 15130.8  $\mu$ m<sup>2</sup>)  
320 were imaged on each hybridized filter piece from 3 $\mu$ m and 0.2 $\mu$ m pore size hybridized filters. The  
321 microscopic evaluation of the hybridized filters was done using a fluorescence microscope (Imager. Z2,  
322 Zeiss, Germany) with 20X air (numerical aperture (NA)= 0.5) and 63X oil (NA= 1.4) objectives. On the  
323 3 $\mu$ m filters we observed predominantly un-hybridized blood cells of different sizes for both Supernatant  
324 and Nycodenz filtrated samples while hybridized bacterial cells were constantly found on the 0.22 $\mu$ m filters  
325 of the Nycodenz filtrated samples, occasionally in very low abundances also on the 0.22 filters of the  
326 Supernatant filtrated samples (data not shown). Bacterial counts were performed only on the 0.22 $\mu$ m filters  
327 from the Nycodenz filtrate layer on 20 to 22 randomly selected fields of view..

## 328 **Results**

### 329 **Contaminant aware analyses allow the derivation of a core blood bacterial** 330 **signature**

331 After filtering and removing contaminating ASVs (**supplementary file 2**), a distinct bacterial profile  
332 remained consisting of 20 phyla (**supplementary file 4**). Of the 2746 detected ASVs, 65 could not be  
333 assigned at the phylum level (2.4%). Assigned taxonomy was dominated by *Proteobacteria* (59.0%),  
334 *Firmicutes* (12.4%), *Patescibacteria* (11.97 %), *Cyanobacteria* (8.9%), and *Actinobacteria* (2.3%),  
335 whereas 5.41% of ASVs belonged to various other phyla.

336 21.6% of all ASVs (592) could not be assigned at the genus level. Assigned ASVs belonged to 314 genera  
337 and the most abundant genera included *Aliterella*, *Anoxybacillus*, *Lactobacillus* and *Sphingomonas* from  
338 the three dominant phyla (**fig 1A**). The core bacterial signature consisting of 10 phyla and 120 genera with  
339 an overall abundance of more than 10% in the dataset could be recovered at each timepoint, although  
340 quantitative changes could be tracked over time and within disease and response groups (see further  
341 results) (**fig 1B,C**).

### 342 **Bacterial community composition is influenced by medication and reflects** 343 **metabolic health**

344 Twenty-seven available host variables (**supplementary tables 4 and 5**) were fit onto genus level RDA in  
345 all available samples with no missing data (n=101). RDA showed that 39.7% of the observed variance  
346 could be explained by the collected host variables ( $R^2= 0.3969$ ,  $R^2_{adj}=0.162$ , p-values of Anova = 0.004).  
347 Associations with RDA ordination on Hellringer transformed abundances were most notable for timepoint  
348 (envfit;  $R^2= 0.2184$ , p=0.001), white blood cell count (envfit:  $R^2 = 0.2531$ , p=0.001), BMI (envfit;  $R^2=$   
349  $0.2219$ , p=0.001), total fat mass (envfit;  $R^2= 0.2090$ , p=0.001), bacterial quantity (envfit;  $R^2= 0.1788$ ,

350 p=0.001) and triglycerides (envfit;  $R^2= 0.1560$ , p=0.001). Several other significant associations with  
351 bacterial composition were observed for general host characteristics such as age, T2D status, MetS status,  
352 sex, anthropometric variables such as waist-to-hip-ratio and visceral fat rating and markers of metabolic  
353 control including HDL-cholesterol and HbA1c as well as inflammation markers like CRP and bacterial  
354 DNA burden (**supplementary table 4**: envfit output for 27 variables on genera level RDA, **supplementary**  
355 **figure 4**). Similar results were observed at ASV levels as well (**supplementary table 5**).  
356 Interestingly, while the number of antihypertensive, antidiabetic and antihyperlipidemic medication was  
357 not correlated with ordination, the use of metformin and PPI significantly contributed to variance in  
358 composition (Metformin  $R^2= 0.0380$ , p=0.022, PPI  $R^2=0.0674$ , p=0.001, **supplementary table 4 and 5**).

## 359 **Blood bacterial signature allows robust classification of subjects with metabolic** 360 **syndrome**

361 Cardiovascular disease and mortality are increased in subjects with MetS [53] even in the absence of  
362 T2D. Because MetS status was significantly associated with bacterial composition beyond single risk  
363 factors used in the MetS definition [27] (**supplementary tables 4 and 5**), we sought to investigate if  
364 bacterial composition could predict MetS status. For this, we applied random forest classification on the  
365 genus as well as phylum level abundances (20 phyla and 314 genera) to develop a classification index. The  
366 resulting MetS classification index (MetS- $I_{\text{genus}}$  and MetS- $I_{\text{phylum}}$ ) could robustly classify subjects along their  
367 actual clinical group at baseline and performed better at genus than at phylum level (AUC $_{\text{genus}}$ =0.816, 95%  
368 CI: 0.661-0.9705 (DeLong) and AUC $_{\text{phylum}}$ =0.740 95% CI: 0.589-0.89 (DeLong) (**fig 2A-D**). MetS-I at  
369 both genus and phylum levels at baseline was correlated with several markers related to obesity, visceral  
370 fat distribution, insulin resistance and inflammation from all timepoints, but was negatively associated with  
371 bacterial DNA load in the blood (**fig 2E, F**). Largest associations with host variables were seen for MetS-  
372  $I_{\text{genus}}$ , which was positively correlated with anthropometric markers related to obesity and insulin  
373 resistance such as total fat mass, waist circumference and WHR. It was also positively associated with

374 inflammation reflected in white blood cells count, CRP and LBP as well as metabolic markers related to  
375 obesity and insulin resistance such as HOMA-IR, HbA1c, glucose, insulin and uric acid. The MetS-I<sub>genus</sub>  
376 was further related to dyslipidemia and hypertension with positive correlations noted for triglyceride levels  
377 and number of antihypertensive drugs while being negatively associated with HDL-cholesterol. Moreover,  
378 both MetS-I<sub>genus</sub> and MetS-I<sub>phylum</sub> were negatively associated with bacterial quantity (**fig 2E,F, table 2**).

## 379 **T2D is characterized by a loss of health associated genera and a decreased ASV** 380 **richness**

381 We investigated bacterial alpha diversity according to T2D status: At baseline subjects with T2D (n=24)  
382 displayed significantly lower observed richness as compared to subjects without T2D (n=24) (mean  
383 observed richness =  $28 \pm 2.31$  vs  $19 \pm 2.10$ ,  $p=0.039$  in subjects without T2D and with T2D respectively;  
384 **fig 3A**). T2D was associated with significant shifts in several genera as compared to subjects without T2D:  
385 At baseline, significantly lower abundances of *Anoxybacillus*, *Duganella*, *Acidibacter* and  
386 *Chryseomicrobium* as well as *Sphingomonas* are found in T2D (**fig 3B**). Furthermore, timepoint seemed to  
387 be relevant for the differences in bacterial abundances between subjects with and with T2D  
388 (**supplementary figures 5A, B**). There were no significantly differentially abundant ASVs between T2D  
389 and nonT2D overlapping between baseline and one year, but the differences between subjects with and  
390 without T2D seemed to be shifting gradually. While subjects with T2D at baseline and three months showed  
391 a reduced abundance in *Sphingomonas*, a common feature seen between T2D at three months and one year  
392 is reduced *Pseudomonas* in T2D. Congruent T2D associated features seen at baseline and one year were  
393 reduced *Bacillaceae* and *Burkholderiaceae* (**supplementary file 7**). Some of the reduced genera in T2D  
394 were expectedly negatively associated with markers of metabolic disease and inflammation such as  
395 *Anoxybacillus* and *Sphingomonas* at baseline with leukocytes and blood pressure respectively (**fig 3C**) as  
396 well as *Paracoccus* with HOMA-IR and leukocytes and *Rhodofera* with markers of obesity at one year  
397 post bariatric surgery (**supplementary figure 5C**). Other genera were surprisingly positively associated

398 with BMI such as *Sphingomonas* (at months three and twelve) or with lipids and blood pressure such as  
399 *Acidibacter* (at baseline, months three and twelve) (**figure 3C, supplementary figure 5C**)

## 400 **Differential response in weight loss and glucose metabolism following bariatric** 401 **surgery**

402 As expected, bariatric surgery had a marked impact on BMI, body composition (WHR, total fat mass and  
403 visceral fat ratio), metabolism as well as inflammation as early as three months post procedure (**table 3**).  
404 From 24 subjects with T2D at baseline, nine subjects were still classified as T2D after three months, and  
405 only four after one year. From patients without T2D at one year, eight had impaired fasting glucose  
406 (prediabetes) and classified therefore as subjects without T2D alleviation after bariatric surgery. From the  
407 total 48 subjects with complete follow-up data, 24 subjects were categorized as good responders (i.e. losing  
408 more than 60% of excess BMI within one year), whereas 13 subjects were classified as poor responders  
409 (**supplementary table 2, supplementary figure 3**). Poor responders not only lost less weight, but also  
410 benefited less from bariatric surgery in regards to improvement of lipid metabolism, insulin resistance or  
411 inflammation, as they still displayed significantly higher HOMA-IR, triglycerides, LDL-Cholesterol and  
412 CRP compared to good responders one year after bariatric surgery (**supplementary table 2**).

## 413 **Reduced bacterial blood load in T2D is ameliorated after bariatric surgery**

414 Bacterial DNA could be measured in 127 blood samples out of 144 samples with available follow-up data  
415 at all three timepoints at a quantity ranging from 4.63 to 140.4 fg in 200 µl blood (median=21.6 fg). Albeit  
416 using the same procedure and the same kit, total extracted DNA varied widely between samples spanning  
417 from 12.7 to 98.2 ng total DNA/µl blood leading to a corrected range of bacterial DNA quantity within 0.08  
418 - 4.11 pg per µg total DNA (median= 0.7 pg bacterial DNA per µg total DNA). While bacterial DNA could  
419 be detected in negative controls at 0.162 pg per total g DNA, total DNA in negative controls did not exceed  
420 1.2 ng/µl leading to total bacterial DNA amounts of less than 1.5 fg (median= 0.4 fg). Overall, bacterial

421 blood load was positively associated with bacterial richness at baseline (**fig 4A**) and negatively with  
422 Leukocytes (**fig 4B**). This observation was further validated in a replication cohort consisting of 62 subjects  
423 from the same center (**supplementary table 3**). Correlation analyses in the replication cohort further  
424 underline the negative associations between inflammation and bacterial load and the association between  
425 LBP and inflammation as well as obesity (**supplementary table 6**).

426 Spanning over all timepoints, bacterial load was negatively correlated with waist circumference, HbA1c,  
427 and inflammation markers such as leukocytes as well as markers related to a presumed leaky gut such as  
428 LBP (**supplementary fig 6A-D, supplementary tables 7 and 8**). The latter was on the other hand  
429 associated with markers of metabolic disease and obesity (**supplementary table 7**). While these  
430 correlations were weak to moderate, the use of Spearman's rank correlation made them less likely to be  
431 influenced by a few high leverage points as shown after removing statistical outliers for bacterial quantity  
432 (**supplementary figure 7A-D**). Accordingly, subjects with T2D at baseline displayed lower bacterial  
433 quantity in both our study and replication cohorts (**fig 4C**).

434 Blood bacterial load was decreased three months post bariatric surgery (median bacterial quantity in pg/ $\mu$ g  
435 at baseline = 0.032, vs 0.024 at three months,  $p=0.013$ , **fig 4D**), but increased significantly at one year  
436 following surgery (median bacterial quantity in pg/ $\mu$ g at one year = 0.062,  $p$ -value compared to three  
437 months= $1.1 \times 10^{-6}$ ,  $p$ -value compared to baseline =0.002, **fig 4D**) independently of T2D status at baseline  
438 (**supplementary figure 8A, B**). When checking the changes according to weight loss response, subjects  
439 deemed 'good responders' and 'poor responders' displayed similar blood bacterial load at baseline (median  
440 bacterial quantity in pg/ $\mu$ g 'good responder' = 0.864 vs 'poor responder' = 0.866,  $p$ -value = 0.9) but blood  
441 bacterial quantity at one year increased less dramatically in good responders and was not significant as  
442 compared the increase in blood bacterial quantity in poor responders (fold change 1.6 vs 2.1 in good vs  
443 poor responders respectively, **fig 4E** ). Bacterial diversity on the hand, showed a transient significant  
444 decrease at three months only to increase again almost to baseline at one year in poor responders, while  
445 continuously and significantly decreasing in good responders (**fig 4F**).

446 LBP, expected to reflect host's response to bacterial DNA, decreased continuously and significantly after  
447 bariatric surgery (median LBP in  $\mu\text{g}/\mu\text{l}$  at baseline = 20.47 vs 15.99 at three months and 6.0 at one year  
448 after bariatric surgery,  $p_{3\text{MonthsvsBaseline}} = 3.3e^{-5}$ ,  $p_{1\text{Yearvs3Months}} = 2.46e^{-6}$   $p_{1\text{YearvsBaseline}} = 5.8e^{-9}$ ) independently of  
449 weight loss response or diabetes status at baseline (**supplementary figures 9A, B**). Similarly, leukocytes  
450 decreased overtime after bariatric surgery but less so and non-significantly in subjects with poor response  
451 (good responders:  $p_{3\text{MonthsvsBaseline}} = 3.3e^{-5}$ ,  $p_{1\text{Yearvs3Months}} = 0.14$  and  $p_{1\text{YearvsBaseline}} = 6.5e^{-4}$  respectively; poor  
452 responders:  $p_{3\text{MonthsvsBaseline}} = 0.67$ ,  $p_{1\text{Yearvs3Months}} = 0.08$  and  $p_{1\text{YearvsBaseline}} = 0.16$ ) (**supplementary fig 9C**).

### 453 **Metabolic improvement after bariatric surgery is accompanied by early** 454 **changes in microbial differential abundances in subjects with and without T2D**

455 Beyond changes in blood bacterial load over time, there were significant and consistent shifts in bacterial  
456 genera over the whole cohort between month three and twelve after bariatric surgery as compared to  
457 baseline. Decreased ASVs belonged to genera such as *Anoxybacillus*, *Rhizobacter* and *Sphingomonas*,  
458 whereas other genera such as *Acinetobacter*, *Granulicatella* and *Pseudomonas* increased. Comparing shifts  
459 at one year and baseline showed that most of these seen at three months post bariatric surgery were  
460 preserved at one year (**fig 5A**).

461 Moreover, T2D remission following bariatric surgery was associated with significantly lower proportions  
462 of *Burkholderiaceae*, *Veilonellaceae* and *Lactobacillaceae* and higher proportions of *Rhodobacteraceae* and  
463 *Pseudomonales* at all timepoints combined (**fig 5B**). Genera with observed shifts after bariatric surgery  
464 were closely tied to metabolic control: Genera, which had a lower abundance after surgery such as  
465 *Anoxybacillus*, *Rhizobacter* and *Sphingomonas* e.g. were significantly positively associated with markers  
466 of body composition such as overall and visceral fat mass, BMI and CRP. Furthermore, significantly  
467 positive correlations were observed for aforementioned genera with markers of metabolic control including  
468 HOMA-IR, number of antidiabetics, uric acid, triglycerides and LDL-Cholesterol (**fig 5D**). As for genera  
469 being more abundant after surgery, *CMIG08* and *Acinetobacter* were negatively associated with markers

470 of central obesity and metabolic disease as well as inflammation, while being positively associated with  
471 HDL-cholesterol and blood bacterial quantity. Contrarily, *Granulicatella* was negatively associated with  
472 excess BMI loss, but positively with sCD14. Of note, while *Granulicatella* was higher at one year compared  
473 to baseline, it seemed to peak at three months, while the increase in *GM1G08* and *Acinetobacter* was  
474 continuous (**fig 5A**). *Paracoccus* – which was shown to be decreased in T2D at baseline and increased in  
475 subjects experiencing T2D remission - was negatively associated with inflammation, fasting glucose,  
476 triglycerides, HOMA-IR and LBP (**fig 5D**).

477 Good responders displayed an increase in ASVs belonging to *Streptococcaceae*, such as *Lactococcus* and  
478 *streptococcus* species, *Burkholderiales* such as *Polaromonas* and *Polynucleobacter*, *Rhodobacteraceae*  
479 such as *Paracoccus* and *Bacillaceae* such as *Anoxybacillus* at all timepoints (**fig 5C**). While *Paracoccus*  
480 was associated with decreased inflammation and metabolic impairment, some genera increased in good vs  
481 poor response were associated with increased BMI and inflammation such as *Anoxybacillus* or *Thermicanus*  
482 overall, but significantly decreased at one year when compared to baseline (**fig.5A**) Several genera  
483 abundantly observed in good responders and subjects who experience T2D remission were initially  
484 decreased in T2D, further delineating a putative positive association with good metabolic health (**fig 3B,**  
485 **5B-D**).

## 486 **CARD-FISH in blood the visualization of living bacteria post bariatric surgery**

487 In order to verify whether increased bacterial quantity post bariatric surgery is only related to uptake of  
488 bacterial sequences or bacteremia, we sought to visualize bacterial cells in a subject, who had undergone  
489 bariatric surgery, in whom blood bacterial quantity could be measured at baseline and for whom bacterial  
490 sequence data are available. CARD-FISH implementation was unsuccessful in frozen blood samples, but  
491 considering blood bacterial quantity increased after surgery over time, we hypothesized that this state is  
492 more likely to yield bacterial cell visualization. Because bacteremia and endotoxemia have been associated  
493 with chewing and food intake [5, 54, 55], blood samples were also collected 1 h after a mixed meal to

494 increase chances of visualization. Similarly, samples were taken from a healthy athletic control, whose  
495 weight has been stable for the last 2 years and who has no known diseases and no medication.

496 Our CARD-FISH results show the presence of bacteria in the blood samples from the patient collected  
497 before and after mixed meal intake with an abundance of  $7.9 \times 10^4$  cells  $\text{mL}^{-1}$  and  $1.2 \times 10^5$  cell  $\text{mL}^{-1}$   
498 respectively (**supplementary figure 10 A,B, Supplementary file 8**) in support of increased bacteremia  
499 after food intake and chewing. In contrast, blood samples from the healthy control revealed no presence of  
500 hybridized bacteria, although filter pieces from all filters ( $3 \mu\text{m}$  and  $0.2 \mu\text{m}$ ) used for cell separation of both  
501 the supernatant and Nycodenz layers were hybridized and imaged (**supplementary figure 10 C,D**). An  
502 additional control to certify the CARD-FISH was successful and the lack of hybridized cells in the healthy  
503 subject is not due to a technical error, same control blood sample was deliberately infected with  
504 *Pseudomonas putida* (DSM6125) (**supplementary figure. 10 E ,F**). Therein, positively hybridized *P. putida*  
505 cells could be observed and no other cell morphotypes, adding evidence that freshly collected blood samples  
506 from the healthy control do not contain bacteria at abundances that can be detected by CARD-FISH.

## 507 **Discussion**

508 The presence of bacteria and bacterial products in various tissues and their contributions to the local and  
509 systemic inflammation have been suggested as novel mechanisms for both development and progression of  
510 “non-communicable” metabolic diseases, such as obesity [13–15, 17, 19, 22], T2D [13–15], cardiovascular  
511 diseases [17] and cirrhosis [18, 56]. However, studies supporting this hypothesis are mostly limited by the  
512 lack of control for contamination and a high overestimation of bacterial DNA quantity, consequently  
513 inflating results. In the present work, we therefore quantified and characterized bacterial DNA in the blood  
514 of subjects with high metabolic burden undergoing bariatric surgery with an emphasis on including and  
515 subtracting suitable negative controls. The goal was to identify links between metabolism and a putative  
516 blood bacterial signature as well as its dynamics over time after bariatric surgery.

517 After stringent experimental and bioinformatic control for contaminants, we report 2746 features (ASVs)  
518 belonging mostly to the phyla *Proteobacteria* and *Firmicutes*, which corroborates previously published  
519 results [13, 14, 21, 56, 57]. Furthermore, we evidence quantitative, compositional and taxonomic signatures  
520 associated with markers of metabolic disease and T2D and shifts thereof driven by medication and weight  
521 loss intervention. We also provide qualitative and quantitative evidence for the presence of bacterial cells  
522 in the blood samples of a subject with obesity, who has undergone bariatric surgery as well as bacteremia  
523 after mixed meal intake in comparison to a healthy control.

524 Our results provide support for the existence of an individually determined core circulatory bacterial  
525 signature and microbiome, which reflects disease and intervention with 40% of observed variance in  
526 bacterial composition explained by 27 host variables prominently related to inflammation, anthropometric  
527 measures as well as metabolic health and medication intake. Of the latter, notable associations of bacterial  
528 signature were seen for metformin and PPI intake. These results underscore findings from other studies  
529 relying on the application of multi-method characterizations including evidence of viability to debunk the  
530 notion that the blood is free of viable microorganisms [14, 56–61] as well as studies showing the deeply  
531 underrated modulatory effect of medication on host microbial communities and the importance of assessing  
532 drug intake in microbial surveys of any niche [62].

533 Moreover, blood bacteria signature allowed the classification of subjects with and without MetS along their  
534 actual clinical group and more accurately so at genus than phylum level. This is in line with recent evidence  
535 showing disease specific tissue signatures in several tissues pertaining to metabolic health as well as cancer  
536 [13, 14, 21] and could be related to the particular vulnerability to translocation of specific ingested bacteria  
537 in respective diseases. Together, these independent observations reinforce the notion of a predictive  
538 circulatory metabolic bacterial signature reminiscent of the described enterotypes [63] in the gut  
539 microbiome.

540 Similarly, we show a specific bacterial signature for T2D characterized by reduced bacterial diversity and  
541 an overall reduction in genera belonging to *Firmicutes* and *Proteobacteria*. Diversity scores were

542 negatively correlated with inflammation, visceral adiposity and uremia, echoing observations of diversity  
543 in gut microbial communities in T2D [64]. Although the reported reduction in genera is in line with data  
544 from Anhê et al., we did not evidence their reported reduction in *Bacteroidetes* nor the increase in *E.coli* in  
545 T2D [13]. While we evidence ASVs belonging to *Bacteroidetes*, their prevalence was very low and was  
546 not particularly associated with metabolic control in our cohort. This could be indeed due either to cohort  
547 specific characteristics or our choice in primers. Our data are more in accordance with results from another  
548 cohort based in our center. On the other hand, we report several more genera in the blood (314 with 120  
549 core genera) compared, which possibly reflects our choice of whole blood as material compared to plasma  
550 samples used by Anhê et al.

551 A hallmark for T2D in our study was the loss of genera related to *Bacillaceae* and *Bukholderiaceae*. Several  
552 of the reduced genera were associated with a healthier metabolic status. Others, such as *Sphingomonas* and  
553 *Acidibacter* were positively associated with BMI and insulin resistance as well as increased blood pressure  
554 and antihyperlipidemic medication respectively. Considering subjects with and without T2D at baseline  
555 were matched on BMI and did not differ significantly in blood pressure nor lipid levels but were  
556 significantly more medicated, these differences could arise from medication effects. This is supported by  
557 evidence from Anhê et al. showing increased *Sphingomonas* in subjects with T2D (at least in Adipose  
558 tissue) and by the fact that these differences disappear after bariatric surgery in our cohort over time, when  
559 subjects are taken off their antihyperlipidemic and antihypertensive medication sequentially.

560 Bariatric surgery, on the other hand, led to swift changes in metabolism and bacterial composition in the  
561 blood: Changes occurring after bariatric surgery take place early on and are mostly stable over time, which  
562 is in line with available data on the rearrangement of the gut microbiome after bariatric surgery [65]. In  
563 addition, subjects who experienced T2D remission showed a significant decrease in several clades  
564 associated with cardiometabolic and cardiovascular disease such as *Streptococcaceae* [66], *Veilonellaceae*  
565 [67] or *Lactobacillales* [68] which are evidenced to be increased in T2D and under diabetic medication in  
566 the gut. In contrast, a few health-related genera increased after bariatric surgery, i.e. genera associated with  
567 improved insulin sensitivity and ameliorated lipid status or reduced adiposity at baseline in our cohort.

568 Similarly, subjects who experience T2D remission after bariatric surgery displayed increases in genera seen  
569 to be initially decreased in T2D, further delineating a positive putative association of these bacteria with  
570 metabolic health.

571 We further investigated circulating bacterial DNA load: Quantification of 16s rRNA showed that bacterial  
572 load was positively associated with bacterial diversity and that the increase of the very small bacterial  
573 quantity observed after bariatric surgery reflects a reduced inflammatory tone and an improved metabolic  
574 health, which we found intriguing. This was also supported by the observations that a) bacterial load is  
575 reduced in T2D at baseline, also in our independently measured replication cohort, b) bacterial load was  
576 negatively associated with metabolic disease index score at baseline, c) bacterial load was associated with  
577 bacterial composition in the opposite direction dictated by metabolic risk factors such as HbA1c, BMI and  
578 TG and that d) it increased after bariatric surgery. This is further corroborated by the fact that all  
579 associations with bacterial quantity are positive with health markers at each and all timepoints. There was  
580 no significant difference in bacterial load at baseline between good and poor responders but poor responders  
581 experienced an even more pronounced increase in bacterial load. Unexpectedly, bacterial diversity  
582 continuously and significantly decreased in good responders, while in poor responders it significantly  
583 dipped around 3 months only to almost recover at one year post bariatric surgery. This was paralleled by  
584 similar dynamics for leukocytes in good responders, while poor responders failed to display a significant  
585 decrease in Leukocytes and inflammation over time. Considering bacterial diversity was still negatively  
586 associated with leukocytes at all timepoints, it seems likely that the superior increase in bacterial quantity  
587 in poor responders is the driving factor behind the observed increased diversity. The latter, on the other  
588 hand and along increased bacterial quantity, could be at least partially responsible for the sustained  
589 inflammation seen at one year in poor responders. Thus, the increased bacterial quantity after bariatric  
590 surgery could be related to increases in gut permeability [69] and transmissibility of oral bacteria after the  
591 surgery due to increased pH [70]. Stronger increases thereof in poor responders are possibly related to an  
592 even more impaired gut permeability due to sustained obesity [71] as well as increased food intake. This  
593 begs the question of the transient reduction in bacterial quantity at three months post bariatric surgery:

594 Considering the origins of bacterial DNA we see is very likely environmental (i.e. food and oral bacteria),  
595 bacterial quantity reduction at three months could be related to the extreme restriction of food intake, far  
596 more pronounced at three months than around one year after surgery where eating behavior and weight loss  
597 are more stable. In support of this, bacterial diversity decreases at three months in both good and poor  
598 responders only to increase in poor responders again, which could indeed be due to increased food intake.  
599 It is important to note that the observations are based on an increase in miniscule amounts of bacterial DNA  
600 far from the expected quantity in clinically relevant bacteremia and sepsis.

601 We would like to acknowledge limitations in our study: Although we control for contamination starting at  
602 DNA isolation including filling EDTA vials with PBS via needle butterflies to take production line  
603 contamination of medical products into account, we cannot fully exclude contamination via puncture of the  
604 skin or other environmental sources. Of note, highest diligence was used in skin decontamination prior to  
605 venipuncture and DNA isolation vials were collected as the last vials (in a sequence of 12 vials). Moreover,  
606 we did not observe typical skin bacteria among identified contaminants, making the skin as a source of  
607 contamination unlikely. Spurious environmental contamination cannot be fully excluded and might explain  
608 the encounter of *Chloroflexi*, *Rhizobacter*, *Limnohabitans* and *Plactomycetes* as well as *uncultured diatom*  
609 in our dataset. While we aimed to reduce these spurious findings as much as possible in a data driven  
610 manner to avoid arbitrary preselection of taxa, even complete subtraction of contaminants AVSs selected  
611 via stringent decontam score as done by Poore et al. [21] did not eliminate these taxa from the dataset  
612 completely. This commends the development of even better pipelines and bioinformatics tools for  
613 decontamination in small bacterial biomass samples. An encouraging observation nonetheless, is that these  
614 taxa do not seem to be particularly relevant for our observed phenotype associations nor does a more  
615 stringent decontamination score change the conclusion of our work, further supporting the emergence of  
616 disease signatures in circulating bacterial composition.

617 We evidence circulatory bacterial DNA but can only speculate about its origins: The translocation of  
618 bacteria from the gut has been the primary considered mechanism. Although this hypothesis is tempting,  
619 we did not validate it by performing gold standard gut permeability tests. Moreover, evidence from the

620 HMP have shown that the blood bacterial signature closely resembles that from the skin and oral cavity  
621 [58], further pointing to alternative or additive origins. Considering transmission of oral strains along the  
622 gastrointestinal tract is more common than previously recognized [72–74] and that gut rearrangement after  
623 bariatric surgery is associated with increased pH in the gut, a shift in bile acid pools [70] and increased PPI  
624 prescription especially after RYGB also evident in our cohort [75], we cannot exclude that the change in  
625 the circulatory blood bacterial signature is reflective of changes in these, among several other bacterial host  
626 niches. The increase in blood bacterial load after bariatric surgery could be seen as underpinning this  
627 hypothesis. While our data make the case, that other mechanisms override an initial increase in gut  
628 permeability, which has been associated with insulin resistance and obesity, to induce weight loss and  
629 improvement of glucose tolerance after bariatric surgery, we are unable to validate this hypothesis at this  
630 point.

631  
632 Finally, the reported correlations on bacterial quantity and those related to bacterial composition with low  
633 effect size should be considered with caution. Despite their statistical significance, the biological relevance  
634 of these associations might be questionable and commends further independent replications.

635 Beyond these restrictions and while the evidence for the presence of bacteria in the placenta has been highly  
636 controversial, with independent groups refuting these findings, there has been no evidence in the literature  
637 that convincingly shows that the blood is a tissue constantly free from bacteria or bacterial genetic material.  
638 The limitations of the several studies linking bacteria in the blood with disease have been addressed in the  
639 present work further adding to its strengths: Diligent sterile handling of materials and pre-treatment of lab  
640 materials with UV-light was employed. We further included several negative controls (PBS for extraction  
641 and blank controls for PCR), while further accounting for production line contamination of medical  
642 products using the same tubes and medical materials used to draw the blood in our subjects. These negative  
643 controls were confirmed in agarose gel but were still sequenced alongside the true samples. Moreover they  
644 were actively used to identify possible contaminants in the dataset which we then excluded using the same  
645 Software, that had helped debunk or at least shake the pertinacious notion of a ‘placenta microbiome’ [76,

646 77]. We further replicated findings on bacterial load in an independent cohort, which was processed and  
647 analyzed independently. Moreover, we could substantiate the associations between host metabolic health  
648 with individual taxa by several different statistical methods while accounting for the impact of relevant  
649 covariates, which has, to our knowledge, never been done performed. Beyond a mere diagnostic tool for  
650 metabolic disease, which can be currently achieved more easily and at a lower cost, the current work  
651 underpins the notion that the blood is a putative ecological niche. Despite extensive immune control it  
652 remains dynamic and reflects metabolic health, warranting further contaminant conscious rigorous work to  
653 delineate mechanistic and exploitable pathways and targets similar to the application of pasteurized bacteria  
654 (e.g. *Akkermansia muciniphila*) [78–83] for weight loss and metabolic improvement.

655

## 656 **Conclusions**

657 In summary, while reducing and controlling both for contamination and technical biases, we could detect  
658 low amounts of bacterial DNA in the blood, where we are able to derive a metabolic fingerprint reflected  
659 in bacterial DNA composition. We could also observe differences in diversity, amount of bacterial DNA  
660 and bacterial composition between subjects with and without T2D, subjects with or without T2D remission  
661 or with varying degrees of weight loss response to bariatric surgery. We further substantiate our findings  
662 of bacterial quantity increase after bariatric surgery with imaging of live bacteria in post bariatric patients.  
663 The present work lays a stepping stone and encourages rigorous cross sectional and longitudinal studies in  
664 larger cohorts with both diseased and healthy subjects. These studies should optimally expand over various  
665 expertise to provide insights into the functionality and potential role of a ‘circulatory microbiome’ in  
666 maintaining health and contributing to the onset and progression of disease.

667 **Abbreviations:**

668 **ALAT:** Alanin-Aminotransferase

669 **ARBs:** Angiotensin II receptor blockers

670 **ASAT:** Aspartat-Aminotransferase

671 **BMI:** Body mass index

672 **CRP:** C-reactive protein

673 **EBL:** Excess BMI loss

674 **eGFR:** Estimated glomerular filtration rate

675 **FPG:** Fasting plasma glucose

676 **GLP1:** Glukagon-like peptide 1

677 **HbA1c:** Glycated Hemoglobin A1c

678 **HDL:** High density lipoprotein;

679 **HOMA-IR:** Homeostatic model assessment for insulin resistance

680 **LBP:** Lipopolysaccharide binding protein

681 **LDL:** Low density lipoprotein

682 **MetS:** Metabolic syndrome

683 **NGT:** Normal glucose tolerance

684 **PPI:** Proton pump inhibitors

685 **RDA:** Redundancy analysis

686 **rRNA:** ribosomal ribonucleic acid

687 **sCD14:** soluble cluster of differentiation 14

688 **T2D:** Type 2 diabetes

689 **WHR:** Waist to hip ratio

## 690 **Declarations**

### 691 **Ethics approval and consent to participate**

692 This study was approved by the ethics committee of the University of Leipzig (application number: 047-  
693 13-28012013) and all participants involved gave written informed consent. The research was performed  
694 in accordance with the principles of the Declaration of Helsinki.

### 695 **Consent for publication**

696 Not applicable

### 697 **Availability of data and materials**

698 The datasets as well as code analyzed and used during the current study are available under reserved  
699 DOIs and will be published after acceptance (citation will be incorporated).

### 700 **Competing interests**

701 The authors have no conflict of interest to declare.

### 702 **Funding**

703 This work was supported by grants from the Deutsche Forschungsgemeinschaft (DFG, German Research  
704 Foundation – Projektnummer 209933838 – SFB 1052; B01, B03, B09) and from IFB AdiposityDiseases  
705 (AD2-060E, AD2-06E95, and AD2-K7-117). IFB Adiposity Diseases is supported by the Federal Ministry  
706 of Education and Research (BMBF), Germany, FKZ: 01EO1501. RC was supported by a junior research  
707 grant by the Medical Faculty, University of Leipzig and by the Federal Ministry of Education and Research

708 (BMBF), Germany, FKZ: 01EO1501 (IFB AdiposityDiseases, MetaRot program). The content of this work  
709 is the responsibility of the authors and does not represent the official views of the funding agencies.

#### 710 **Author contributions**

711 RC and PK designed the study; RC performed experiments; RC and LM analyzed the data; NM supervised  
712 and conducted CARD-FISH experiments and analyzed related downstream data. NS performed  
713 quantification of bacterial cells after CARD-FISH. All authors contributed to manuscript preparation and  
714 writing.

#### 715 **Acknowledgment**

716 We would like to thank Stefanie Walther, Judith Kammer, Charlott Krahnepuhl and Eileen Bösenberg for  
717 their excellent support in recruiting subjects, supervising subjects during the study and aftercare,  
718 organization and coordination of the studies, and sample, as well as diligent data collection. We also thank  
719 Stefanie Ziesche for excellent technical assistance in the lab. We would further like to thank all subjects  
720 who took part in the study and without whom this research would not have been possible. We acknowledge  
721 the Centre for Chemical Microscopy (ProVIS) at the Helmholtz Centre for Environmental Research for  
722 using their sample preparation and microscopy facilities. Special thanks to Katja Nerlich for support during  
723 in situ hybridization and fluorescence microscopy image acquisition. **Supplementary figures 1 and 3** were  
724 created using BioRender.com.

## 725 References

- 726 1. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut  
727 microbiome with increased capacity for energy harvest. *Nature*. 2006;444:1027–31.  
728 doi:10.1038/nature05414.
- 729 2. Sommer F, Bäckhed F. The gut microbiota--masters of host development and physiology. *Nat Rev*  
730 *Microbiol*. 2013;11:227–38. doi:10.1038/nrmicro2974.
- 731 3. Karlsson F, Tremaroli V, Nielsen J, Bäckhed F. Assessing the human gut microbiota in metabolic  
732 diseases. *Diabetes*. 2013;62:3341–9. doi:10.2337/db13-0844.
- 733 4. Zhang X, Shen D, Fang Z, Jie Z, Qiu X, Zhang C, et al. Human Gut Microbiota Changes Reveal the  
734 Progression of Glucose Intolerance. *PLoS One* 2013. doi:10.1371/journal.pone.0071108.
- 735 5. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, et al. Metabolic endotoxemia initiates  
736 obesity and insulin resistance. *Diabetes*. 2007;56:1761–72. doi:10.2337/db06-1491.
- 737 6. Le Chatelier E, Nielsen T, Qin J, Prifti E, Hildebrand F, Falony G, et al. Richness of human gut  
738 microbiome correlates with metabolic markers. *Nature*. 2013;500:541–6. doi:10.1038/nature12506.
- 739 7. Cotillard A, Kennedy SP, Kong LC, Prifti E, Pons N, Le Chatelier E, et al. Dietary intervention impact  
740 on gut microbial gene richness. *Nature*. 2013;500:585–8. doi:10.1038/nature12480.
- 741 8. Vandeputte D, Kathagen G, D'hoë K, Vieira-Silva S, Valles-Colomer M, Sabino J, et al. Quantitative  
742 microbiome profiling links gut community variation to microbial load. *Nature*. 2017;551:507–11.  
743 doi:10.1038/nature24460.
- 744 9. Zhang H, DiBaise JK, Zuccolo A, Kudrna D, Braidotti M, Yu Y, et al. Human gut microbiota in obesity  
745 and after gastric bypass. *Proc Natl Acad Sci U S A*. 2009;106:2365–70. doi:10.1073/pnas.0812600106.
- 746 10. Furet J-P, Kong L-C, Tap J, Poitou C, Basdevant A, Bouillot J-L, et al. Differential Adaptation of Human  
747 Gut Microbiota to Bariatric Surgery–Induced Weight Loss: Links With Metabolic and Low-Grade  
748 Inflammation Markers. *Diabetes*. 2010;59:3049–57. doi:10.2337/db10-0253.
- 749 11. Graessler J, Qin Y, Zhong H, Zhang J, Licinio J, Wong M-L, et al. Metagenomic sequencing of the  
750 human gut microbiome before and after bariatric surgery in obese patients with type 2 diabetes:  
751 correlation with inflammatory and metabolic parameters. *Pharmacogenomics J*. 2013;13:514–22.  
752 doi:10.1038/tpj.2012.43.
- 753 12. McLaughlin RW, Vali H, Lau PCK, Palfree RGE, Ciccio A de, Sirois M, et al. Are there naturally  
754 occurring pleomorphic bacteria in the blood of healthy humans? *J Clin Microbiol*. 2002;40:4771–5.  
755 doi:10.1128/jcm.40.12.4771-4775.2002.
- 756 13. Anhê FF, Jensen BAH, Varin TV, Servant F, van Blerk S, Richard D, et al. Type 2 diabetes influences  
757 bacterial tissue compartmentalisation in human obesity. *Nat Metab*. 2020;2:233–42.  
758 doi:10.1038/s42255-020-0178-9.
- 759 14. Massier L, Chakaroun R, Tabei S, Crane A, Didt KD, Fallmann J, et al. Adipose tissue derived bacteria  
760 are associated with inflammation in obesity and type 2 diabetes. *Gut* 2020. doi:10.1136/gutjnl-2019-  
761 320118.
- 762 15. Amar J, Serino M, Lange C, Chabo C, Iacovoni J, Mondot S, et al. Involvement of tissue bacteria in  
763 the onset of diabetes in humans: evidence for a concept. *Diabetologia*. 2011;54:3055–61.  
764 doi:10.1007/s00125-011-2329-8.
- 765 16. Qiu J, Zhou H, Jing Y, Dong C. Association between blood microbiome and type 2 diabetes mellitus:  
766 A nested case-control study. *J Clin Lab Anal*. 2019;33:e22842. doi:10.1002/jcla.22842.
- 767 17. Amar J, Lange C, Payros G, Garret C, Chabo C, Lantieri O, et al. Blood microbiota dysbiosis is  
768 associated with the onset of cardiovascular events in a large general population: the D.E.S.I.R. study.  
769 *PLoS One*. 2013;8:e54461. doi:10.1371/journal.pone.0054461.
- 770 18. Schierwagen R, Alvarez-Silva C, Madsen MSA, Kolbe CC, Meyer C, Thomas D, et al. Circulating  
771 microbiome in blood of different circulatory compartments. *Gut*. 2019;68:578–80. doi:10.1136/gutjnl-  
772 2018-316227.

- 773 19. Sato J, Kanazawa A, Ikeda F, Yoshihara T, Goto H, Abe H, et al. Gut dysbiosis and detection of "live  
774 gut bacteria" in blood of Japanese patients with type 2 diabetes. *Diabetes Care*. 2014;37:2343–50.  
775 doi:10.2337/dc13-2817.
- 776 20. Lelouvier B, Servant F, Païssé S, Brunet A-C, Benyahya S, Serino M, et al. Changes in blood  
777 microbiota profiles associated with liver fibrosis in obese patients: A pilot analysis. *Hepatology*.  
778 2016;64:2015–27. doi:10.1002/hep.28829.
- 779 21. Poore GD, Kopylova E, Zhu Q, Carpenter C, Fraraccio S, Wandro S, et al. Microbiome analyses of  
780 blood and tissues suggest cancer diagnostic approach. *Nature*. 2020;579:567–74.  
781 doi:10.1038/s41586-020-2095-1.
- 782 22. Ortiz S, Zapater P, Estrada JL, Enriquez P, Rey M, Abad A, et al. Bacterial DNA translocation holds  
783 increased insulin resistance and systemic inflammatory levels in morbid obese patients. *J Clin  
784 Endocrinol Metab*. 2014;99:2575–83. doi:10.1210/jc.2013-4483.
- 785 23. Salter SJ, Cox MJ, Turek EM, Calus ST, Cookson WO, Moffatt MF, et al. Reagent and laboratory  
786 contamination can critically impact sequence-based microbiome analyses. *BMC Biol*. 2014;12:87.  
787 doi:10.1186/s12915-014-0087-z.
- 788 24. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2020. *Diabetes  
789 Care*. 2020;43:S14-S31. doi:10.2337/dc20-S002.
- 790 25. Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, et al. 2017  
791 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention,  
792 Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A  
793 Report of the American College of Cardiology/American Heart Association Task Force on Clinical  
794 Practice Guidelines. *Circulation*. 2018;138:e426-e483. doi:10.1161/CIR.0000000000000597.
- 795 26. Catapano AL, Graham I, Backer G de, Wiklund O, Chapman MJ, Drexel H, et al. 2016 ESC/EAS  
796 Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of  
797 Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society  
798 (EAS) Developed with the special contribution of the European Association for Cardiovascular  
799 Prevention & Rehabilitation (EACPR). *Atherosclerosis*. 2016;253:281–344.  
800 doi:10.1016/j.atherosclerosis.2016.08.018.
- 801 27. Alberti KGMM, Zimmet P, Shaw J. The metabolic syndrome--a new worldwide definition. *Lancet*.  
802 2005;366:1059–62. doi:10.1016/S0140-6736(05)67402-8.
- 803 28. Dirksen C, Jørgensen NB, Bojsen-Møller KN, Kielgast U, Jacobsen SH, Clausen TR, et al. Gut  
804 hormones, early dumping and resting energy expenditure in patients with good and poor weight loss  
805 response after Roux-en-Y gastric bypass. *Int J Obes (Lond)*. 2013;37:1452–9. doi:10.1038/ijo.2013.15.
- 806 29. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. *Diabetes Care*.  
807 2004;27:1487–95. doi:10.2337/diacare.27.6.1487.
- 808 30. Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermúdez-Humarán LG, Gratadoux J-J, et al.  
809 *Faecalibacterium prausnitzii* is an anti-inflammatory commensal bacterium identified by gut microbiota  
810 analysis of Crohn disease patients. *Proc Natl Acad Sci U S A*. 2008;105:16731–6.  
811 doi:10.1073/pnas.0804812105.
- 812 31. Valladares R, Sankar D, Li N, Williams E, Lai K-K, Abdelgeliel AS, et al. *Lactobacillus johnsonii* N6.2  
813 mitigates the development of type 1 diabetes in BB-DP rats. *PLoS One*. 2010;5:e10507.  
814 doi:10.1371/journal.pone.0010507.
- 815 32. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR  
816 and the 2<sup>-</sup>(-Delta Delta C(T)) Method. *Methods*. 2001;25:402–8. doi:10.1006/meth.2001.1262.
- 817 33. Cole JR, Wang Q, Fish JA, Chai B, McGarrell DM, Sun Y, et al. Ribosomal Database Project: data and  
818 tools for high throughput rRNA analysis. *Nucleic Acids Res*. 2013;42:D633-42.  
819 doi:10.1093/nar/gkt1244.
- 820 34. Wickham H. *ggplot2: Elegant Graphics for Data Analysis*.
- 821 35. Kassambara A. *ggpubr: Publication Reday Plots*.

- 822 36. Wei T. corrplot: Visualization of a Correlation Matrix.
- 823 37. McMurdie PJ, Holmes S. phyloseq: An R Package for Reproducible Interactive Analysis and Graphics  
824 of Microbiome Census Data. *PLoS One* 2013. doi:10.1371/journal.pone.0061217.
- 825 38. Ewels P, Magnusson M, Lundin S, Källér M. MultiQC: summarize analysis results for multiple tools and  
826 samples in a single report. *Bioinformatics*. 2016;32:3047–8. doi:10.1093/bioinformatics/btw354.
- 827 39. Bolyen E, Rideout JR, Dillon MR, Bokulich NA, Abnet CC, Al-Ghalith GA, et al. Reproducible,  
828 interactive, scalable and extensible microbiome data science using QIIME 2. *Nat Biotechnol*.  
829 2019;37:852–7. doi:10.1038/s41587-019-0209-9.
- 830 40. Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJA, Holmes SP. DADA2: High-resolution  
831 sample inference from Illumina amplicon data. *Nat Methods*. 2016;13:581–3. doi:10.1038/nmeth.3869.
- 832 41. Katoh K, Misawa K, Kuma K-i, Miyata T. MAFFT: a novel method for rapid multiple sequence alignment  
833 based on fast Fourier transform. *Nucleic Acids Res*. 2002;30:3059–66. doi:10.1093/nar/gkf436.
- 834 42. Pedregosa F, Varoquaux G, Gramfort A, Michel V, Thirion B, Grisel O. Scikit-learn: Machine Learning  
835 in Python. <http://arxiv.org/abs/1201.0490>.
- 836 43. Quast C, Pruesse E, Yilmaz P, Gerken J, Schweer T, Yarza P, et al. The SILVA ribosomal RNA gene  
837 database project: improved data processing and web-based tools. *Nucleic Acids Res*. 2013;41:D590-  
838 6. doi:10.1093/nar/gks1219.
- 839 44. Davis NM, Proctor DM, Holmes SP, Relman DA, Callahan BJ. Simple statistical identification and  
840 removal of contaminant sequences in marker-gene and metagenomics data. *Microbiome*. 2018;6:226.  
841 doi:10.1186/s40168-018-0605-2.
- 842 45. Oksanen J. *Vegan: Community Ecology Package*. Ordination methods, diversity analysis and other  
843 functions for community and vegetation ecologists | *World Agroforestry*.
- 844 46. Lahti L, Shetty S, Blake T. *microbiome* R package.
- 845 47. Liaw A. *randomForest: Breiman and Cutler's Random Forests for Classification and Regression*.
- 846 48. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez J-C, Müller M. pROC: an open-source  
847 package for R and S+ to analyze and compare ROC curves. *BMC Bioinformatics*. 2011;12:77.  
848 doi:10.1186/1471-2105-12-77.
- 849 49. Evans JS MMA. *rfUtilities*; 2018.
- 850 50. Murphy MA, Evans JS, Storfer A. Quantifying *Bufo boreas* connectivity in Yellowstone National Park  
851 with landscape genetics. *Ecology*. 2010;91:252–61. doi:10.1890/08-0879.1.
- 852 51. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data  
853 with DESeq2. *Genome Biol*. 2014;15:550. doi:10.1186/s13059-014-0550-8.
- 854 52. Pernthaler A, Pernthaler J. Simultaneous fluorescence in situ hybridization of mRNA and rRNA for the  
855 detection of gene expression in environmental microbes. *Meth Enzymol*. 2005;397:352–71.  
856 doi:10.1016/S0076-6879(05)97021-3.
- 857 53. Lakka H-M, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT. The  
858 metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. *JAMA*.  
859 2002;288:2709–16. doi:10.1001/jama.288.21.2709.
- 860 54. Forner L, Larsen T, Kilian M, Holmstrup P. Incidence of bacteremia after chewing, tooth brushing and  
861 scaling in individuals with periodontal inflammation. *J Clin Periodontol*. 2006;33:401–7.  
862 doi:10.1111/j.1600-051X.2006.00924.x.
- 863 55. Amar J, Chabo C, Waget A, Klopp P, Vachoux C, Bermúdez-Humarán LG, et al. Intestinal mucosal  
864 adherence and translocation of commensal bacteria at the early onset of type 2 diabetes: molecular  
865 mechanisms and probiotic treatment. *EMBO Mol Med*. 2011;3:559–72.  
866 doi:10.1002/emmm.201100159.
- 867 56. Traykova D, Schneider B, Chojkier M, Buck M. Blood Microbiome Quantity and the Hyperdynamic  
868 Circulation in Decompensated Cirrhotic Patients. *PLoS One* 2017. doi:10.1371/journal.pone.0169310.

- 869 57. Païssé S, Valle C, Servant F, Courtney M, Burcelin R, Amar J, Lelouvier B. Comprehensive description  
870 of blood microbiome from healthy donors assessed by 16S targeted metagenomic sequencing.  
871 *Transfusion*. 2016;56:1138–47. doi:10.1111/trf.13477.
- 872 58. Whittle E, Leonard MO, Harrison R, Gant TW, Tonge DP. Multi-Method Characterization of the Human  
873 Circulating Microbiome. *Front Microbiol*. 2018;9:3266. doi:10.3389/fmicb.2018.03266.
- 874 59. Moriyama K, Ando C, Tashiro K, Kuhara S, Okamura S, Nakano S, et al. Polymerase chain reaction  
875 detection of bacterial 16S rRNA gene in human blood. *Microbiol Immunol*. 2008;52:375–82.  
876 doi:10.1111/j.1348-0421.2008.00048.x.
- 877 60. Dinakaran V, Rathinavel A, Pushpanathan M, Sivakumar R, Gunasekaran P, Rajendhran J. Elevated  
878 Levels of Circulating DNA in Cardiovascular Disease Patients: Metagenomic Profiling of Microbiome  
879 in the Circulation. *PLoS One* 2014. doi:10.1371/journal.pone.0105221.
- 880 61. Olde Loohuis LM, Mangul S, Ori APS, Jospin G, Koslicki D, Yang HT, et al. Transcriptome analysis in  
881 whole blood reveals increased microbial diversity in schizophrenia. *Transl Psychiatry* 2018.  
882 doi:10.1038/s41398-018-0107-9.
- 883 62. Maier L, Pruteanu M, Kuhn M, Zeller G, Telzerow A, Anderson EE, et al. Extensive impact of non-  
884 antibiotic drugs on human gut bacteria. *Nature*. 2018;555:623–8. doi:10.1038/nature25979.
- 885 63. Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, et al. Enterotypes of the human  
886 gut microbiome. *Nature*. 2011;473:174–80. doi:10.1038/nature09944.
- 887 64. Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, et al. A metagenome-wide association study of gut microbiota  
888 in type 2 diabetes. *Nature*. 2012;490:55–60. doi:10.1038/nature11450.
- 889 65. Palleja A, Kashani A, Allin KH, Nielsen T, Zhang C, Li Y, et al. Roux-en-Y gastric bypass surgery of  
890 morbidly obese patients induces swift and persistent changes of the individual gut microbiota. *Genome*  
891 *Med*. 2016;8:67. doi:10.1186/s13073-016-0312-1.
- 892 66. Koren O, Spor A, Felin J, Fåk F, Stombaugh J, Tremaroli V, et al. Human oral, gut, and plaque  
893 microbiota in patients with atherosclerosis. *Proc Natl Acad Sci U S A*. 2010;108:4592–8.  
894 doi:10.1073/pnas.1011383107.
- 895 67. Yoshida N, Yamashita T, Hirata K-i. Gut Microbiome and Cardiovascular Diseases. *Diseases* 2018.  
896 doi:10.3390/diseases6030056.
- 897 68. Forslund K, Hildebrand F, Nielsen T, Falony G, Le Chatelier E, Sunagawa S, et al. Disentangling type  
898 2 diabetes and metformin treatment signatures in the human gut microbiota. *Nature*. 2015;528:262–6.  
899 doi:10.1038/nature15766.
- 900 69. Blanchard C, Moreau F, Chevalier J, Ayer A, Garçon D, Arnaud L, et al. Sleeve Gastrectomy Alters  
901 Intestinal Permeability in Diet-Induced Obese Mice. *Obes Surg*. 2017;27:2590–8. doi:10.1007/s11695-  
902 017-2670-1.
- 903 70. Aron-Wisnewsky J, Doré J, Clement K. The importance of the gut microbiota after bariatric surgery.  
904 *Nat Rev Gastroenterol Hepatol*. 2012;9:590–8. doi:10.1038/nrgastro.2012.161.
- 905 71. Chakaroun RM, Massier L, Kovacs P. Gut Microbiome, Intestinal Permeability, and Tissue Bacteria in  
906 Metabolic Disease: Perpetrators or Bystanders? *Nutrients* 2020. doi:10.3390/nu12041082.
- 907 72. Lockhart PB, Brennan MT, Sasser HC, Fox PC, Paster BJ, Bahrani-Mougeot FK. Bacteremia  
908 associated with toothbrushing and dental extraction. *Circulation*. 2008;117:3118–25.  
909 doi:10.1161/CIRCULATIONAHA.107.758524.
- 910 73. Parahitiyawa NB, Jin LJ, Leung WK, Yam WC, Samaranayake LP. Microbiology of Odontogenic  
911 Bacteremia: beyond Endocarditis. *Clin Microbiol Rev*. 2009;22:46–64. doi:10.1128/CMR.00028-08.
- 912 74. Schmidt TS, Hayward MR, Coelho LP, Li SS, Costea PI, Voigt AY, et al. Extensive transmission of  
913 microbes along the gastrointestinal tract. *Elife* 2019. doi:10.7554/eLife.42693.
- 914 75. Geraldo MdSP, Fonseca FLA, Gouveia MRdFV, Feder D. The use of drugs in patients who have  
915 undergone bariatric surgery. *Int J Gen Med*. 2014;7:219–24. doi:10.2147/IJGM.S55332.

- 916 76. Goffau MC de, Lager S, Sovio U, Gaccioli F, Cook E, Peacock SJ, et al. Human placenta has no  
917 microbiome but can contain potential pathogens. *Nature*. 2019;572:329–34. doi:10.1038/s41586-019-  
918 1451-5.
- 919 77. Davis NM, Proctor DM, Holmes SP, Relman DA, Callahan BJ. Simple statistical identification and  
920 removal of contaminant sequences in marker-gene and metagenomics data. *Microbiome*. 2018;6:226.  
921 doi:10.1186/s40168-018-0605-2.
- 922 78. Cani PD, Vos WM de. Next-Generation Beneficial Microbes: The Case of *Akkermansia muciniphila*.  
923 *Front Microbiol*. 2017;8:1765. doi:10.3389/fmicb.2017.01765.
- 924 79. Depommier C, Everard A, Druart C, Plovier H, van Hul M, Vieira-Silva S, et al. Supplementation with  
925 *Akkermansia muciniphila* in overweight and obese human volunteers: a proof-of-concept exploratory  
926 study. *Nat Med*. 2019;25:1096–103. doi:10.1038/s41591-019-0495-2.
- 927 80. Druart C, Plovier H, Hul M, Brient A, Phipps KR, Vos WM de, Cani PD. Toxicological safety evaluation  
928 of pasteurized *Akkermansia muciniphila*. *J Appl Toxicol* 2020. doi:10.1002/jat.4044.
- 929 81. Hänninen A, Toivonen R, Pöysti S, Belzer C, Plovier H, Ouwerkerk JP, et al. *Akkermansia muciniphila*  
930 induces gut microbiota remodelling and controls islet autoimmunity in NOD mice. *Gut*. 2018;67:1445–  
931 53. doi:10.1136/gutjnl-2017-314508.
- 932 82. Katiraei S, Vries MR de, Costain AH, Thiem K, Hoving LR, van Diepen JA, et al. *Akkermansia*  
933 *muciniphila* Exerts Lipid-Lowering and Immunomodulatory Effects without Affecting Neointima  
934 Formation in Hyperlipidemic APOE\*3-Leiden.CETP Mice. *Mol Nutr Food Res*. 2020;64:e1900732.  
935 doi:10.1002/mnfr.201900732.
- 936 83. Plovier H, Everard A, Druart C, Depommier C, Hul M, Geurts L, et al. A purified membrane protein from  
937 *Akkermansia muciniphila* or the pasteurized bacterium improves metabolism in obese and diabetic  
938 mice. *Nat Med*. 2017;23:107–13. doi:10.1038/nm.4236.
- 939

## 940 **Figure Legends**

941 **Figure 1** contaminant aware blood bacterial signatures at a decontam score of 0.175 **(A)** Top 25 genera and  
942 their respective taxonomic classification. The bandwidth is proportional to the amount of ASVs within each  
943 Phylum, genera are ordered from bottom to top within each family according to alphabetical order ,  
944 taxonomy was generated with all available baseline samples (n=64) and follow-up samples at three months  
945 (n=48) and one year (n=48) **(B)** Relative abundance of phyla within samples with follow-up sequencing at  
946 all timepoints: Baseline (n=48), three months (n=48) and one year (n=48) after bariatric surgery. Phyla with  
947 an abundance within the whole dataset of less than 10% are flagged under the category '<10% Abundance'.  
948 Taxonomy is shown for matched subjects with and without T2D (n for each group =24) at each timepoint  
949 separately. **(C)** Relative abundance of core genera belonging to the phyla with an abundance of >10% within  
950 samples with follow-up sequencing at all timepoints: Baseline (n=48), three months (n=48) and one year  
951 (n=48) after bariatric surgery. Taxonomy is shown for matched subjects with and without T2D (n for each  
952 group =24) at each timepoint separately.

953  
954 **Figure 2** Bacterial blood signature derived metabolic syndrome classification index. Probability of being  
955 classified as subject with metabolic syndrome using random forest classification of Phyla and genera  
956 abundances (n Phyla=20 , n genera=314 , in 47 subjects – 36 with and 11 without MetS , missing n=1,  
957 nondiabetic, not unambiguously categorized) **(A, B)** corresponding Area under the curve for both genus  
958 and phylum level random forest models for metabolic syndrome prediction respectively **(C,D)** MetS-I<sub>Genus</sub>  
959 and MetS-I<sub>Phylum</sub> respectively in subjects with and without Metabolic syndrome, boxplots with Tukey-  
960 whiskers and mean (◆) are shown. Unpaired samples Wilcoxon signed-rank test is used to compare groups  
961 and nominal p-values are shown. **(E, F)** Spearman's rank correlations of MetS-I<sub>Genus</sub> and MetS-I<sub>Phylum</sub> at  
962 baseline with host variables from all timepoints. Nominal significant values are indicated: \*: p<0.05, \*\*: p<0.01, \*\*\*: p<0.001.

964

965 **Figure 3 (A)** Observed Richness between subjects with (n=24) and without T2D (n=24), boxplots with  
966 Tukey-whiskers and mean (◆) as well as median are shown. Unpaired samples Wilcoxon signed-rank test  
967 is used to compare groups and nominal p-value is shown. **(B)** Differentially abundant genera in subjects  
968 with T2D (n=24) compared to subjects without T2D (n=24) at baseline. Differential abundance is calculated  
969 at ASV level using taxonomy after stringent control for contamination at a decontam score of 0.5 and  
970 reported at genus level. **(C)** Spearman's rank correlations of relative selected genera abundance with host  
971 parameters at baseline. Selection included genera seen to be differentially abundant between groups (i.e.  
972 T2D, good/poor responders and T2D alleviation vs no T2D alleviation). Only genera are shown with at  
973 least one significant correlation with host markers. (+) refers to p-value < 0.05. Color represents correlation  
974 strength (Rho) according to color legend. *Abbreviations:* HDL: high density lipoprotein; LDL: low density  
975 lipoprotein; WHR: Waist-hip-ratio; BMI: Body mass index; CRP: C-reactive protein; sCD14: soluble  
976 cluster of differentiation 14; LBP: Lipopolysaccharide binding protein; EBL: Excess BMI loss.

977  
978 **Figure 4 (A)** Spearman's rank correlation of bacterial load at baseline with alpha diversity (Simpson Index)  
979 the grey area around regression line indicates the confidence interval at a confidence level of 95%. **(B)**  
980 Spearman's rank correlation of bacterial load at baseline with Leukocytes in the study and replication  
981 cohort. Colors depict cohorts with red being specific to the study cohort and blue to the replication cohort.  
982 Bacterial quantity is standardized within cohorts. The grey area around regression line indicates the  
983 confidence interval at a confidence level of 95%. **(C)** Blood bacterial in load in T2D vs nonT2D in both  
984 study and replication cohort. Bacterial quantity was standardized prior to statistical analysis. Boxplots are  
985 shown with Tukey-whiskers and mean (◆) as well as median. T2D was compared with nonT2D using  
986 Wilcoxon signed rank test after pooling both cohorts. **(D)** Bacterial quantity in pg per µg extracted DNA  
987 over time. The three timepoints are compared using Kruskal-Wallis test and results are validated via  
988 Friedman's test (Kruskal-Wallis p-value is depicted). Paired samples Wilcoxon signed-rank test is used to  
989 compare two groups at once. Only samples with available triplicates in blood bacterial load are used for the  
990 comparisons (n=39). **(E)**-Bacterial quantity dynamics in good and poor responders over time (n=21 good

991 responders, n=13 poor responders). The three timepoints are compared using Kruskal-Wallis test and results  
992 are validated via Friedman's test (Kruskal-Wallis p-value is depicted). Paired samples Wilcoxon signed-  
993 rank test is used to compare two groups at once. **(F)** Diversity dynamics in good and poor responders over  
994 time (n=24 good responders, n=13 poor responders). The three timepoints are compared using Kruskal-  
995 Wallis test and results are validated via Friedman's test (Kruskal-Wallis p-value is depicted). Paired  
996 samples Wilcoxon signed-rank test is used to compare two groups at once.

997

998 **Figure 5 (A)** Differentially abundant genera between baseline and 3 months (blue bars) and baseline and  
999 one year (red) within the complete cohort with available taxonomy at all timepoints (n=48). Differential  
1000 abundance is calculated on ASV level abundances using taxonomy after stringent control for  
1001 decontamination at a decontam score 0.5 and reported at genus level. Only significant differential  
1002 abundances ( $P_{adj} < 0.01$ ) are reported. **(B)** Differentially abundant genera in subjects with T2D, who  
1003 experienced diabetes remission as compared to those with persistent T2D (n=12 in both groups). Color  
1004 shading represents p-values. **(C)** Differentially abundant genera in good responders vs poor responders  
1005 (n=24 vs 13 respectively). Color shading represents p-values. **(D)** Spearman's rank correlations of  
1006 differentially abundant genera in good responders and subjects with T2D remission with host variables in  
1007 all timepoints. (+) indicates a significance level  $<0.05$ .

1008

1009 **Tables**

**Table 1 Baseline cohort characteristics of subjects with complete follow-up**

Baseline characteristics	NGT	T2D	P-value
N	24	24	
<b>General</b>			
Sex (F/M)	18/6	17/7	1
Age (years)	46.8 ± 8.59	50.1 ± 7.94	<b>0.007</b>
BMI (kg/m <sup>2</sup> )	50.8 ± 6.59	49.0 ± 6.68	0.943
WHR	0.91 [0.87;0.95]	0.98 [0.99;1.03]	<b>0.006</b>
GFR (ml/min/1.73m <sup>2</sup> )	93.8 [80.6;114]	94.0 [79.6;110]	0.996
Smoking status			
Active smokers, N (%)	2 (8.70%)	3 (12.5%)	1
<b>Glycemia, insulin resistance and antidiabetic medication intake</b>			
HbA1c (%)	5.38 [5.29;5.58]	6.56 [5.95;8.22]	<b>&lt; 0.001</b>
FPG (mmol/l)	5.25 [4.98;5.42]	7.42 [6.54;11.7]	<b>&lt; 0.001</b>
HOMA-IR	3.10 [2.27;4.53]	8.59 [5.71;13.8]	<b>&lt; 0.001</b>
Nr antidiabetics	0.00 [0.00;0.00]	1.00 [1.00;3.00]	<b>&lt;0.001</b>
<b>Hypertension status and antihypertensive medication</b>			
Hypertension, N (%)	16 (66.7%)	22 (91.7%)	0.076
Number of anti-HTN drugs, N	1.00 [1.00;3.00]	3.50 [1.00;5.00]	0.067
Systolic blood pressure (mmHg)	131 ± 11.0	133 ± 14.7	0.665
Diastolic blood pressure (mmHg)	76.8 ± 8.26	76.4 ± 15.1	0.924
<b>Dyslipidemia and antihyperlipidemic medication intake</b>			
LDL-C (mmol/l)	3.25 ± 0.87	3.09 ± 0.93	0.545
HDL-C (mmol/l)	1.27 [1.02;1.52]	1.10 [0.94;1.30]	0.105
TG (mmol/l)	1.52 (0.69)	1.67 [1.42;2.24]	<b>0.017</b>
Statin, N (%)	1 (4.17%)	7 (29.2%)	<b>0.048</b>
Ezetimib, N (%)	0.00 (0.00%)	2 (8.33%)	0.489
<b>Blood and Inflammatory markers</b>			
Haemoglobin (g/dl)	13.4 [13.0;14.5]	14.2 [13.4;14.9]	0.115
Leucocytes (Gpt/l)	6.70 [5.25;7.20]	8.30 [7.65;10.7]	<b>&lt; 0.001</b>
CRP (pg/ml)	10.4 [3.47;17.9]	8.72 [5.24;22.8]	0.546

1010 Median and first, as well as third, quartile limits (median [q1; q3]) are shown for non-normally distributed, continuous  
 1011 variables. For normally distributed, continuous variables data are given in mean ± standard deviation (mean ± SD).  
 1012 For categorical parameters, total numbers (percentage) are shown. Significant p-values are depicted in bold.  
 1013 Abbreviations: **BMI**: Body mass index; **CRP**: C-reactive protein; **FPG**: Fasting plasma glucose; **HbA1c**: Glycated  
 1014 Hemoglobin A1c; **HDL**: High-density lipoprotein; **HOMA-IR**: Homeostatic model assessment for insulin  
 1015 resistance; **LDL**: Low-density lipoprotein; **NGT**: Normal glucose tolerance; **T2D**: Type 2 diabetes; **TG**:  
 1016 Triglycerides; **WHR**: Waist to hip ratio.  
 1017

1018 **Table 2 Spearman Correlations between MetS-Igenus at baseline with host variables (n=141: 47**  
1019 **subjects at 3 timepoints)**

	Rho	p-value
Variables		
CRP	0.21	* <0.05
Fasting glucose	0.2	* <0.05
Triglycerides	0.2	* <0.05
HDL-Cholesterol	-0.19	* <0.05
HbA1c	0.33	*** <0.0001
Insulin	0.27	* <0.5
Total fat mass	0.26	** <0.01
Number of antihypertensive drugs	0.27	** <0.01
Platelet count	0.38	*** <0.0001
Serum albumin	0.18	* <0.05
Uric acid	0.2	* <0.05
White blood cell count	0.38	*** <0.0001
LBP	0.25	** <0.001
Bacterial quantity	-0.23	* <0.05

1020

**Table 3 Clinical and biological characteristics of study cohort subjects before, 3 and 12 months after bariatric surgery procedure**

	Baseline N=48	Three months post bariatric surgery N=48	One year post bariatric surgery N=48
<b>General and body composition</b>			
<b>Sex (F/M)</b>		32/12	
<b>Metabolic syndrome status, N (%)</b>	36/47 (76.6) <sup>A</sup>	17/41 (41.5) <sup>B</sup>	10/43 (23.3) <sup>C</sup>
<b>Diabetes status, N (%)</b>	24 (50.0) <sup>A</sup>	9(18.7) <sup>B</sup>	4(8.3) <sup>C</sup>
<b>BMI (kg/m<sup>2</sup>)</b>	49.7± 6.50 <sup>A</sup>	41.3 ± 5.85 <sup>B</sup>	35.1± 5.62 <sup>C</sup>
<b>WHR</b>	0.95 [0.91;1.02] <sup>A</sup>	0.94 [0.88;0.99] <sup>A</sup>	0.94 [0.87;1.01] <sup>A</sup>
<b>Total fat mass (in %)</b>	49.4 [43.3;53.0] <sup>A</sup>	46.0 [38.8;48.2] <sup>B</sup>	37.0 [28.9;44.0] <sup>C</sup>
<b>Visceral fat mass ratio</b>	19.0 [17.0;22.0] <sup>A</sup>	15.0 [12.8;16.0] <sup>B</sup>	12.0 [8.00;13.0] <sup>C</sup>
<b>Glycemia, insulin resistance and antidiabetic medication intake</b>			
<b>HbA1c (%)</b>	5.62 [5.42;6.66] <sup>A</sup>	5.42 [5.17;5.77] <sup>B</sup>	5.21 [4.89;5.64] <sup>C</sup>
<b>FPG (mmol/l)</b>	5.50 [5.21;7.54] <sup>A</sup>	5.25 [4.89;6.04] <sup>B</sup>	5.00 [4.68;5.57] <sup>C</sup>
<b>HOMA-IR</b>	5.37 [3.16;8.85] <sup>A</sup>	2.62 [2.12;2.93] <sup>B</sup>	2.30 [1.07;3.15] <sup>B</sup>
<b>Hypertension status</b>			
<b>Systolic blood pressure (mmHg)</b>	132 ± 12.9 <sup>A</sup>	120 ± 14.9 <sup>B</sup>	120 ± 14.7 <sup>B</sup>
<b>Diastolic blood pressure (mmHg)</b>	76.6 ± 12.1 <sup>A</sup>	68.2 ± 13.0 <sup>A</sup>	68.8 ± 11.4 <sup>A</sup>
<b>Dyslipidemia and antihyperlipidemic medication intake</b>			
<b>LDL-C (mmol/l)</b>	3.16 [2.48;3.81] <sup>A</sup>	2.26 [1.92;2.83] <sup>B</sup>	2.37 [1.93;2.91] <sup>B</sup>
<b>HDL-C (mmol/l)</b>	1.21 [0.99;1.40] <sup>A</sup>	1.12 [0.96;1.35] <sup>A</sup>	1.52 [1.27;1.59] <sup>B</sup>
<b>TG (mmol/l)</b>	1.68 [1.28;2.15] <sup>A</sup>	1.15 [0.94;1.46] <sup>B</sup>	0.96 [0.64;1.30] <sup>C</sup>
<b>Blood and Inflammatory markers</b>			
<b>Leucocytes (Gpt/l)</b>	7.50 [6.70;8.50] <sup>A</sup>	6.60 [5.50;8.03] <sup>A</sup>	6.10 [5.20;7.32] <sup>A</sup>
<b>LBP (µg/ml)</b>	20.465[17.89;24.21] <sup>A</sup>	15.99 [11.75;17.59] <sup>B</sup>	6.005 [2.36;14.01] <sup>C</sup>
<b>sCD14 (ng/ml)</b>	3089 ± 384 <sup>A</sup>	3626 ± 323 <sup>B</sup>	3243 ± 385 <sup>C</sup>
<b>CRP (pg/ml)</b>	8.61 [3.87;18.8] <sup>A</sup>	4.56 [1.49;10.1] <sup>B</sup>	1.24 [0.43;3.52] <sup>C</sup>
<b>Bacterial DNA amount (in pg per µg extracted whole DNA)</b>	0.64 [0.48;1.05] <sup>A</sup>	0.48 [0.32;0.68] <sup>B</sup>	1.24 [0.90;2.03] <sup>C</sup>

1021 Median and first, as well as third, quartile limits (median [q1; q3]) are shown for non-normally distributed, continuous  
 1022 variables. For normally distributed, continuous variables, data are given in mean ± standard deviation (mean ± SD).  
 1023 For categorical parameters, total numbers (percentage) are shown. Significant p-values are depicted according to group  
 1024 differences: the difference between 2 values in a row with the same letter are non-significant. **Abbreviations: BMI:**  
 1025 Body mass index; **CRP:** C-reactive protein; **FPG:** Fasting plasma glucose; **HbA1c:** Glycated Hemoglobin  
 1026 A1c; **HDL:** High density lipoprotein; **HOMA-IR:** Homeostatic model assessment for insulin resistance; **LBP:**  
 1027 Lipopolysaccharide binding protein; **LDL:** Low density lipoprotein; **sCD14:** soluble CD14; **TG:**  
 1028 Triglycerides; **WHR:** Waist to hip ratio.  
 1029

1030 **Supplementary Material**

1031 **Supplementary Tables**

**Table 1 baseline cohort characteristics with initial matching (n=64)**

Baseline characteristics	NGT	T2D	P-value
N	32	32	
<b>General</b>			
Sex (F/M)	24/8	24/8	
Age (years)	40.5 [31.0;45.5]	49 [41.8; 52.2]	<b>0.025</b>
BMI (kg/m <sup>2</sup> )	50.3 ± 6.5	50.2 ± 6.07	0.943
WHR	0.91[0.86; 0.95]	0.98 [ 0.92; 1.05]	<b>0.001</b>
Active smokers, N (%)	4 (12.5%)	8 (25%)	0.337
<b>Glycemia, insulin resistance and antidiabetic medication intake</b>			
HbA1c (%)	5.38 [5.25;5.51]	6.58 [5.95;7.64]	< <b>0.001</b>
FPG (mmol/l)	5.19 [4.86;5.35]	7.21 [5.83;9.71]	< <b>0.001</b>
HOMA-IR	3.46 [2.83;5.35]	7.30 [4.96;12.5]	<b>0.001</b>
Number of anti-T2D drugs (N)	0	2.00 [2.00;3.00]	< <b>0.001</b>
Insulin therapy, N (%)	0	8 (25.0%)	< <b>0.001</b>
Metformin, N (%)	0	23 (71.9%)	< <b>0.001</b>
Sulfonylureas, N (%)	0	2 (6.25%)	< <b>0.001</b>
DPPIV-Inhibitors, N (%)	0	24 (75.0%)	< <b>0.001</b>
GLP1-Agonists, N (%)	0	6 (18.8%)	< <b>0.001</b>
<b>Hypertension status and antihypertensive medication</b>			
Hypertension, N (%)	20 (62.5%)	26 (81.2%)	0.164
Number of anti-HTN drugs, N	1.00 [0.00;2.00]	2.00 [0.75;3.25]	0.287
Beta-blockers, N (%)	12 (37.5%)	12 (37.5%)	1
ACE-Inhibitors, N (%)	7 (21.9%)	19 (59.4%)	<b>0.005</b>
ARBs, N (%)	7 (21.9%)	4 (12.5%)	0.508
Calcium channel blockers, N (%)	4 (12.5%)	7 (21.9%)	0.508
Loop diuretics, N (%)	3 (9.38%)	7 (21.9%)	0.302
K-sparing diuretics, N (%)	0	1 (3.12%)	1
Thiazide diuretics, N (%)	5 (15.6%)	15 (46.9%)	<b>0.008</b>
Systolic blood pressure (mmHg)	129 ±10.7	130 ± 13.3	0.753
Diastolic blood pressure (mmHg)	75.1 ± 9.99	75.7 ±14.2	0.852
<b>Dyslipidemia and antihyperlipidemic medication intake</b>			
LDL-C (mmol/l)	3.06 ± 0.79	3.06 ± 0.85	0.974
HDL-C (mmol/l)	1.23 [0.99;1.48]	1.15 [0.95;1.28]	0.170
TG (mmol/l)	1.58 [1.15;1.85]	1.67 [1.42;2.24]	0.143
Statin, N (%)	1 (3.12%)	8 (25.0%)	<b>0.014</b>
Ezetimib, N (%)	0	1 (3.12%)	1
<b>Blood and inflammatory markers</b>			
CRP (pg/ml)	12.4 [3.47;18.2]	10.6 [6.08;26.1]	0.294

1032 Median and first, as well as third, quartile limits (median [q1; q3]) are shown for non-normally distributed, continuous  
 1033 variables. For normally distributed, continuous variables data are given in mean ± standard deviation (mean ± SD).  
 1034 For categorical parameters, total numbers (percentage) are shown. Significant p-values are depicted in bold.  
 1035 Abbreviations: **ARBs**: Angiotensin II receptor blockers; **BMI**: Body mass index; **CRP**: C-reactive protein; **FPG**:  
 1036 Fasting plasma glucose; **GLP1**: Glukagon-like peptide 1, **HbA1c**: Glycated Hemoglobin A1c; **HDL**: High density  
 1037 lipoprotein; **HOMA-IR**: Homeostatic model assessment for insulin resistance; **LDL**: Low density  
 1038 lipoprotein; **NGT**: Normal glucose tolerance; **T2D**: Type 2 diabetes; **TG**: Triglycerides; **WHR**: Waist to hip ratio.

1039

1040

**Supplementary Table 2 Phenotypes of good vs poor responders at baseline and one year post bariatric surgery**

Baseline characteristics	Good Responder		Poor Responder		P-value	
	baseline	One year	baseline	One year	baselines	One year
N	24		13			
<b>General</b>						
Sex (F/M)	17/7		10/3			
Age (years)	46.3 ± 8.87	46.3 ± 8.87	48.2 ± 6.14	48.2 ± 6.14	0.79	
BMI (kg/m <sup>2</sup> )	47.7 ± 5.59	30.8 2.97	51.7 ± 6.58	40.9 ± 3.39	0.14	
WHR	0.96 ± 0.11	0.91 [0.86;0.98]	0.93 ± 0.06	0.94 [0.90;0.96]	0.82	
Visceral fat ratio	18.8 ± 4.69	8.00 [6.00;9.25]	21.2 ± 5.97	13.0 [13.0;15.0]	0.46	
<b>Glycemia, insulin resistance and metabolic syndrome at baseline</b>						
T2D Status (Yes)	11 (45.8%)	2 (8.33%)	9 (69.2%)	2 (15.4%)	0.46	0.6
HbA1c (%)	6.56 ± 1.70	5.13 [4.80;5.44]	6.24 ± 1.16	5.41 [4.94;5.96]	0.78	0.24
FPG (mmol/l)	7.28 ± 3.46	5.01 [4.66;5.57]	7.22 ± 3.07	5.33 [4.78;5.81]	1	0.44
HOMA-IR	13.8 ± 25.9	1.24 [0.77;2.72]	7.00 ± 7.55	3.20 [2.53;3.53]	0.63	<b>0.02</b>
Antidiabetic N	9 (37.5%)	2 (8.33%)	9 (69.2%)	2 (15.4%)	0.27	0.60
MetS Status	19 (79.2%)	4 (18.2%)	9 (69.2%)	4 (33.3%)	1	0.60
<b>Hypertension status and antihypertensive medication</b>						
Systolic RR (mmHg)	129 ± 13.5	118 ± 15.9	137 ± 12.5	124 ± 13.2	0.30	0.23
Diastolic RR (mmHg)	76.0 ± 12.3	67.3 ± 10.7	76.0 ± 11.8	69.9 ± 11.7	1	0.5
<b>Dyslipidemia and antihyperlipidemic medication intake</b>						
LDL-C (mmol/l)	3.18 ± 1.04	2.08 [1.83;2.68]	3.24 ± 0.69	2.67 [2.42;2.97]	0.98	<b>0.03</b>
HDL-C (mmol/l)	1.26 ± 0.40	1.54 [1.33;1.74]	1.25 ± 0.25	1.52 [1.35;1.55]	0.99	0.44
TG (mmol/l)	1.84 ± 0.84	0.86 [0.62;1.08]	1.75 ± 0.59	1.21 [1.01;1.50]	0.93	<b>0.03</b>
Statin, N (%)	4 (16.0%)	4 (16.7%)	3 (23.1%)	3 (23.1%)	0.96	0.67
<b>Blood and Inflammatory markers</b>						
Haemoglobin (g/dl)	13.9 ± 1.18	13.1 ± 1.21	13.7 ± 0.64	13.0 ± 1.21	0.88	0.83
Leucocytes (Gpt/l)	7.99 ± 2.45	6.23 ± 1.58	7.65 ± 1.75	6.84 ± 1.89	0.88	0.33
CRP (pg/ml)	11.7 ± 9.86	0.94 [0.38;1.60]	14 ± 11.8	3.41 [1.12;5.36]	0.95	<b>0.018</b>
Bacterial load fg/ng	0.86 ± 0.62	1.11 [0.74;1.80]	0.87 ± 0.62	1.49 [1.24;2.50]	1	0.14

1041 Continuous variables data are given in mean ± standard deviation. Median and first, as well as third, quartile limits  
 1042 (median [q1; q3]) are shown for non-normally distributed. For categorical parameters, total numbers (percentage) are  
 1043 shown. Significant p-values are depicted in bold. Abbreviations: **BMI**: Body mass index; **CRP**: C-reactive  
 1044 protein; **FPG**: Fasting plasma glucose; **HbA1c**: Glycated Hemoglobin A1c; **HDL**: High density  
 1045 lipoprotein; **HOMA-IR**: Homeostatic model assessment for insulin resistance; **LDL**: Low density  
 1046 lipoprotein; **NGT**: Normal glucose tolerance; **RR**: Blood pressure (Riva Rocci) **T2D**: Type 2 diabetes; **TG**:  
 1047 Triglycerides; **WHR**: Waist to hip ratio.

**Supplementary Table 3 Replication Cohort characteristics**

Baseline characteristics	NGT	T2D	P-value
N	37	25	
<b>General</b>			
Sex (F/M)	27/10	16/9	0.57
Age (years)	44 ± 11	53 ± 11	<b>0.003</b>
BMI (kg/m <sup>2</sup> )	46.28 ± 5.63	48.46 ± 7.4	0.38
<b>Glycemia, insulin resistance and lipid metabolism</b>			
FPG (mmol/l)	5.41 ± 1.07	7.06 ± 1.93	<b>0.001</b>
HOMA-IR	4.70 ± 3.91	9.23 ± 12.68	0.11
Triglycerides (mmol/l)	1.28 ± 0.76	2.25 ± 2.22	0.05
HDL-Cholesterol (mmol/l)	1.16 ± 0.34	0.98 ± 0.28	<b>0.04</b>
LDL-Cholesterol (mmol/l)	2.84 ± 0.72	2.57 ± 0.86	0.2
<b>Inflammatory markers</b>			
Leukocytes (Gpt)	8.08 ± 2.24	8.54 ± 2.33	0.44
LBP	11.72 ± 4.00	14.33 ± 6.26	0.07

1048 Data are given in mean ± standard deviation (mean ± SD). For categorical parameters, total numbers (percentage) are  
 1049 shown. Significant p-values are depicted in bold. **Abbreviations:** **BMI:** Body mass index; **CRP:** C-reactive  
 1050 protein; **FPG:** Fasting plasma glucose; **HbA1c:** Glycated Hemoglobin A1c; **HOMA-IR:** Homeostatic model  
 1051 assessment for insulin resistance; **LBP:** Lipopolysaccharide binding protein

1052

1053 **Supplementary Table 4: Envfit output for 27 variables on genera level RDA**

Variables	RDA1	RDA2	R <sup>2</sup>	Adj. P(r)
BMI	1.00000	0.00007	0.2219	0.001***
Systolic blood pressure	0.73835	-0.67441	0.0158	0.487
eGFR	0.09266	-0.99570	0.0053	0.780
CRP_us	0.81536	-0.57896	0.0667	0.025*
HbA1c	0.50241	-0.86463	0.0753	0.027*
HDL- cholesterol	-0.99377	0.11144	0.0963	0.016*
LDL-cholesterol	-0.91281	0.40839	0.0231	0.306
triglycerides	0.88166	0.47189	0.1560	0.001***
Total fat mass in %	0.96126	-0.27565	0.2090	0.001***
Visceral fat rating	0.79766	-0.60310	0.0719	0.030*
Nr of antidiabetics	0.99683	0.07956	0.0541	0.069
Nr of antihypertensives	-0.65734	-0.75359	0.0008	0.964
Nr of antihyperlipidemics	-0.07182	0.99742	0.0135	0.514
White blood cells count	0.87696	-0.48055	0.2531	0.001***
Age	-0.75498	-0.65575	0.0653	0.034*
Bacterial quantity	-0.99870	0.05102	0.1788	0.001***
Waist-to-hip-ratio	-0.24996	-0.96826	0.0860	0.015*
Diabetes Status _ No	-4.5303	5.4529	0.0630	0.002**
Diabetes Status _ Yes	16.2677	-19.5809		
Sex_female	4.2702	3.6557	0.0318	0.039*
Sex_male	-12.3180	-10.5452		
Metformin intake_No	-4.0974	-0.8525	0.0380	0.022*
Metformin intake_Yes	25.4624	5.2977		
PPI intake No	-16.5911	7.6883	0.0674	0.001***
PPI intake Yes	9.5917	-4.4448		
Timepoint_baseline	20.2299	9.4054	0.2184	0.001***
Timepoint_one_year	-31.7231	-7.1606		
Timepoint_three_months	16.9608	0.2972		
Metabolic syndrome No	-10.5658	7.8723	0.0886	0.001***
Metabolic Syndrome Yes	15.4622	-11.5205		
T2D Alleviation_ Yes	14.2149	-2.4049	0.0278	0.068
T2D Alleviation_No	-5.4523	0.9224		
EBL_ good responder	-4.0761	7.9539	0.0389	0.082
EBL_ medium_responder	9.7610	-2.1739		
EBL_ poor_responder	1.8058	-13.0851		
Surgical procedure_RYGB	-0.6923	21.583	0.0147	0.220
Surgical procedure_Sleeve	56.641	-176.590		

1054

1055 **Supplementary Table 5: Envfit output for 27 variables on ASV level RDA**

Variables	RDA1	RDA2	R <sup>2</sup>	Adj. P(r)
BMI	0.99700	-0.07735	0.2549	0.001***
Systolic blood pressure	0.39658	0.91800	0.0862	0.016*
eGFR	0.14059	0.99007	0.0328	0.181
CRP_us	0.92738	-0.37411	0.0580	0.059
HbA1c	0.54979	0.83530	0.0828	0.026*
HDL- cholesterol	-0.92841	0.37155	0.1038	0.010**
LDL-cholesterol	-0.72935	-0.68414	0.0276	0.255
triglycerides	0.87812	-0.47844	0.1622	0.002**
Total fat mass in %	0.99994	0.01054	0.1999	0.001***
Visceral fat rating	0.98608	-0.16627	0.0635	0.043*
Nr of antidiabetics	0.93161	0.36347	0.0737	0.030*
Nr of antihypertensives	0.03295	-0.99946	0.0124	0.557
Nr of antihyperlipidemics	-0.17617	-0.98436	0.0023	0.906
White blood cells count	0.84021	0.54226	0.3037	0.001***
Age	-0.97574	-0.21895	0.0343	0.171
Bacterial quantity	-0.97013	-0.24259	0.2082	0.001***
Waist-to-hip-ratio	0.99994	0.01054	0.1999	0.001***
Diabetes Status _ No	-4.7134	-6.2159	0.0829	0.001***
Diabetes Status _ Yes	16.9256	22.3208		
Sex_female	3.7401	0.2824	0.0154	0.214
Sex_male	-10.7886	-0.8147		
Metformin intake_No	-4.2775	0.4924	0.0437	0.013*
Metformin intake_Yes	26.5815	-3.0602		
PPI intake No	-14.8085	6.8333	0.0583	0.002***
PPI intake Yes	8.5612	-3.9505		
Timepoint_baseline	21.4085	-6.1564	0.2333	0.001***
Timepoint_one_year	-31.0180	9.5650		
Timepoint_three_months	15.3955	-5.0725		
Metabolic syndrome No	-9.7827	-5.1334	0.0678	0.001***
Metabolic Syndrome Yes	14.3161	7.5123		
T2D Alleviation_ Yes	12.3703	-2.7700	0.0234	0.108
T2D Alleviation_No	-4.7448	1.0625		
EBL_ good responder	-3.8266	-6.2655	0.0468	0.052
EBL_ medium_responder	10.0702	-6.9565		
EBL_ poor_responder	1.1815	15.2199		
Surgical procedure_RYGB	-0.8286	-0.2355	0.0023	0.804
Surgical procedure_Sleeve	6.7793	1.9271		

1056

**Supplementary Table 6 Spearman's rank correlations between bacterial load and LBP with host variables in the replication cohort**

Covariate 1	Covariate 2	Beta-coefficient	P-value
Bacterial load in pg/ $\mu$ g isolated DNA	<b>Circ. TNF-<math>\alpha</math></b>	<b>-0.26</b>	<b>0.04</b>
	LBP	-0.138	0.29
	HbA1c (%)	-0.12	0.33
	HOMA-IR	-0.20	0.11
	<b>Leukocytes count (in Gpt/l)</b>	<b>-0.38</b>	<b>&lt;0.001</b>
LBP	<b>BMI</b>	<b>0.32</b>	<b>0.008</b>
	<b>CRP</b>	<b>0.35</b>	<b>0.005</b>
	<b>HOMA-IR</b>	<b>0.28</b>	<b>0.03</b>
	HbA1c	0.24	0.06
	<b>Leukocytes count</b>	<b>0.29</b>	<b>0.02</b>

1057 **Abbreviations:** BMI: Body mass index; CRP: C-reactive protein; FPG: Fasting plasma glucose; HbA1c: Glycated  
 1058 Hemoglobin A1c; HOMA-IR: Homeostatic model assessment for insulin resistance; LBP: Lipopolysaccharide  
 1059 binding protein, TNF-  $\alpha$ : Tumor necrosis factor alpha

1060

**Supplementary Table 7 Spearman's rank correlations between bacterial load and LBP with host variables in the study cohort**

Timepoint	Covariate 1	Covariate 2	Beta-coefficient	P-value
baseline	Bacterial load in fg/ng isolated DNA	Observed microbial richness	0.33	<0.05
		Leukocytes	-0.45	<0.01
All tim points	LBP	HbA1c (%)	-0.24	<0.01
		Uric acid in mmol/l	-0.24	<0.01
		Total fat mass (kg)	-0.19	<0.05
		Total weight (kg)	-0.21	<0.05
		Waist circumference	-0.21	<0.05
		Platelet count	-0.31	<0.001
		Leukocytes count (in Gpt/l)	-0.38	<0.001
		LBP	-0.274	<0.05
		BMI	0.47	< 0.001
		WHR	0.34	<0.05
		HOMA-IR	0.32	<0.05
		HbA1c	0.4	<0.05
		Number of antidiabetics	0.35	<0.05
		Leukocytes count	0.36	<0.05

1061

1062

1063

**Supplementary Table 8 Spearman's rank correlations between bacterial load and host variables in the study cohort at baseline and the replication cohort (for which only baseline is available)**

	Study cohort			Replication cohort			Combined		
	$\rho$	p	N	$\rho$	p	N	$\rho$	p	N
<b>BMI</b>	-0.074	0.612	50	-0.087	0.502	62	-0.089	0.351	112
<b>HOMA-IR</b>	-0.027	0.872	37	-0.216	0.106	57	-0.151	0.146	94
<b>Triglycerides</b>	0.346*	0.013	51	-0.325*	0.013	58	-0.019	0.842	109
<b>LBP</b>	-0.122	0.446	41	-0.167	0.224	55	-0.138	0.181	96
<b>Leukocytes</b>	<b>0.450**</b>	<b>0.001</b>	<b>51</b>	<b>-0.334**</b>	<b>0.008</b>	<b>62</b>	<b>-0.388**</b>	<b>2.1x10-5</b>	<b>113</b>
<b>Fasting plasma glucose (mmol/l)</b>	0.112	0.486	41	-0.173	0.178	62	-0.048	0.632	103
<b>Cholesterol (mmol/l)</b>	0.194	0.174	51	0.016	0.908	58	0.091	0.348	109
<b>HDL-cholesterol</b>	-0.319*	0.022	51	-0.028	0.834	58	-0.158	0.101	109
<b>LDL-cholesterol</b>	0.178	0.212	51	0.148	0.266	58	0.158	0.101	109

1064

## 1065 **Supplementary Figures Legends**

1066 **Supplementary Figure 1** Flowchart with number of subjects / Datasets and ASVs in each reported  
1067 analyses

1068

1069 **Supplementary Figure 2** Number of ASVs with respective prevalence along Decontam scores: The  
1070 contaminant scores show a bimodal distribution with low scores for lower prevalence ASVs around 0.1,  
1071 higher prevalence ASVs (in which we are confident) start to rise beyond the threshold of 0.175.

1072

1073 **Supplementary Figure 3** flowchart showing T2D alleviation and response after bariatric surgery

1074

1075 **Supplementary Figure 4** correlation Triplot fitted site scores as linear combinations of the environmental  
1076 variables and constraints (explanatory variables), highly significant variables with  $p < 0.002$  are shown in  
1077 red. First two canonical axes are visualized. Species scores are shown as red crosses, samples are shown as  
1078 green triangles; Arrowheads depict significant explanatory variables and their directional contribution to  
1079 the variance in the dataset.

1080

1081 **Supplementary Figure 5 (A)** Differentially abundant genera in subjects with T2D (n=9) compared to  
1082 subjects without T2D (n=39) at 3 months post bariatric surgery. Differential abundance is calculated at  
1083 ASV level using taxonomy after stringent control for contamination at a decontam score of 0.5 and reported  
1084 at genus level. **(B)** Differentially abundant genera in subjects with T2D (n=4) compared to subjects without  
1085 T2D (n=44) at one year post bariatric surgery. Differential abundance is calculated on ASV level using  
1086 taxonomy after stringent control for contamination at a decontam score of 0.5 and reported at genus  
1087 level. Color shading represents p-values. **(C)** Spearman's rank correlations of relative selected genera  
1088 abundance with host parameters at 3 months and one year post bariatric surgery. Selection included genera  
1089 seen to be differentially abundant between groups (i.e. T2D, good/poor responders and T2D alleviation vs

1090 no T2D alleviation). Only genera are shown with at least one significant correlation with host markers. (+)  
1091 refers to  $p$ -value  $< 0.05$ . Color represents correlation strength (Rho) according to color legend.

1092

1093 **Supplementary Figure 6 (A-D)** Spearman's rank correlations of bacterial quantity in pg per total  $\mu\text{g}$   
1094 extracted DNA with markers or inflammation and metabolic disease over all timepoints. The grey area  
1095 around regression line indicates the confidence interval at a confidence level of 95%.

1096

1097 **Supplementary Figure 7 (A-D)** Spearman's rank correlations of bacterial quantity in pg per total  $\mu\text{g}$   
1098 extracted DNA with markers or inflammation and metabolic disease over all timepoints after removing  
1099 statistical outliers for bacterial quantity. The grey area around regression line indicates the confidence  
1100 interval at a confidence level of 95%.

1101 **Supplementary Figure 8** bacterial quantity over time according to T2D and non T2D (A,B) respectively.  
1102 Four samples with missing baseline bacterial quantity were eliminated. Boxplots are shown with Tukey-  
1103 whiskers and mean ( $\blacklozenge$ ) as well as median. The three timepoints are compared using Kruskal-Wallis test  
1104 and results are validated via Friedman's test (Kruskal-Wallis  $p$ -value is depicted). Paired samples Wilcoxon  
1105 signed-rank test is used to compare two groups at once.






1106 **Supplementary Figure 9 (A)** Changes in LBP over time in good vs poor responders. (B) Changes in LBP  
1107 over time on subjects with and without T2D at baseline (C) Changes in leukocytes over time in good vs  
1108 poor responders. Boxplots are shown with Tukey-whiskers and mean ( $\blacklozenge$ ) as well as median. The three  
1109 timepoints are compared using Kruskal-Wallis test and results are validated via Friedman's test (Kruskal-  
1110 Wallis  $p$ -value is depicted). Paired samples Wilcoxon signed-rank test is used to compare two groups at  
1111 once.

1112


1113 **Supplementary Figure 10** Representative epifluorescence micrographs obtained by green light excitation  
1114 and UV excitation of hybridized blood samples using CARD-FISH with HRP-labelled EUB338 probe (in

1115 red) and DAPI staining (in blue). **(A-B)** Positively hybridized bacterial cells (arrows) in fresh blood  
1116 collected before mixed meal intake **(A)** and after mixed meal intake **(B)** from patient (5 years post bariatric  
1117 surgery). **(C-D)** Healthy control blood samples collected before **(C)** and after **(D)** mixed meal intake shows  
1118 no hybridized bacterial cells. Instead, the auto-fluorescence of blood cells can be observed upon increased  
1119 exposure. **(E-F)** Control of CARD-FISH efficiency on blood samples collected from the healthy control  
1120 before **(E)** and after **(F)** mixed meal intake and deliberately infected with *Pseudomonas putida* (Red) prior  
1121 to hybridization shows positively hybridized cells of *P. putida* (arrows) as expected. In blue, DAPI staining  
1122 of blood cells is observed. Scale bar 10  $\mu\text{m}$  for all images







A




B



C





## Differentially abundant genera:

